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Obesity is correlated with insulin resistance and elevated levels of glucose, 
triglycerides and free fatty acids in blood. This affects overall metabolism and leads to 
disease. In the obese state, fat also accumulates in non-adipose tissue including liver, 
muscle and pancreas, where it can lead to cellular dysfunction and death. Currently, only 
a limited number of drugs are available to combat obesity and it is clear that new drugs, 
which more narrowly target the metabolic pathways involved, are required. Fatty Acid 
Transport Proteins (FATPs) are bifunctional proteins involved in the uptake and 
activation of fatty acids by esterification with coenzyme A. Inhibition of uptake of fatty 
acids in non-adipose tissues seem an attractive mechanism for treatment of lipotoxicity 
and obesity related diseases. In this study, we have investigated a newly identified fatty 
acid uptake inhibitor called CB5/Grassofermata (2-benzyl-3-(4-chlorophenyl)-5-(4-
nitrophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one) that presumably works through 
interaction with Fatty Acid Transport Protein (FATP)-2.  
In the present study we demonstrate the ability of CB5/Grassofermata to inhibit 
uptake of fatty acids in cell lines that are models for liver, small intestines, pancreas and 
muscle in low micro-molar ranges (IC50: 8-11µM). The inhibition was less effective in 
human adipocytes, model for adipose tissue (IC50: 58µM). Also, we show that CB5 
specifically inhibits the uptake of long-chain (C12-C20) and very long-chain (≥C22) fatty 
	  	  
ii	  
acids and protects liver and pancreatic cells from lipotoxicity generated by palmitic acid. 
Pharmacokinetic analysis of CB5 demonstrated its ability to limit absorption of labeled 
oleate across intestinal epithelium after 6hrs of oral administration (300mg/kg). Finally, 
we used whole body knockout mice of FATP2 gene on high fat and low fat (60% and 
12% energy from fat, respectively) diets to understand the implications of loss of FATP2 
gene on lipid metabolism. Loss of FATP2 gene resulted in ~35% reduction in plasma 
triglycerides levels and demonstrated increased steatosis after 12 weeks on diets. Hepatic 
steatosis was likely caused by the expression of FATP5, ACSL1 and ACSL5 transport 
proteins causing increased accumulation of hepatic triglycerides reflected in the amount 
of saturated and monounsaturated fatty acid. These diet studies are important prior of 
using CB5 in diet-induced obesity mice models.
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CHAPTER 1 
BACKGROUND AND SIGNIFICANCE 
Fatty Acid in diseased states 
The rising prevalence of obesity and related disorders is an increasing global threat 
predicting a decrease in the life expectancy of future generations [1, 2]. According to 
2011-2012 data, more than one-third (34.9%) of US adults and 17% of children and 
adolescents (between 2-19 years) were obese. Since 1980, obesity among children has 
tripled in United States [3]. A major part of the risk is the increasing prevalence of the 
pathogenic events that follow obesity; which includes, but is not restricted to, insulin 
resistance (IR), metabolic syndrome (MS), type II diabetes mellitus (T2DM), non-
alcoholic fatty liver disease (NAFLD) and cardiovascular diseases (CVD) [2]. The 
etiology of these diseases is still poorly understood as they continue to pose burden on 
the health management sectors in developed countries.  
 
The inability of the body to utilize/oxidize the excessive incoming fat for energy 
purposes causes progressive weight gain. This imbalance between fatty acid uptake and 
utilization has been associated with insulin resistance, pancreatic ß-cell dysfunction, 
hepatocyte cell death and cardiomyocyte dysfunction [4]. The inability of insulin to 
control the uptake of glucose and fatty acids by various organs serves as first step 
towards disease condition, a state called insulin resistance. The insensitivity of the organs 
to respond to insulin, leads to an increase in the levels of free fatty acid (FFA) in 
circulation, which is thought to be the result of uncontrolled lipolysis in adipose tissue 
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[5]. This increase in circulating FFA leads to the excessive uptake of FFA by non-adipose 
tissue such as liver, pancreas, muscle and heart. This ectopic accumulation of FFA in 
non-adipose tissues leads to a state of lipotoxicity, which results in cellular dysfunction, 
cell death and eventually organ dysfunction (Figure 1A) [6, 7]. Thus, it is clear that in 
order to understand the etiology of these diseases, it is important to understand the 
mechanism of selective uptake and retention of fatty acids in the cell. 
 
	  
Figure 1A: Progression of lipotoxicity and related disease states. Over-nutrition leads to 
progressive weight gain, increase in the levels of circulating free fatty acids and excessive lipid 
accumulation in non-adipose tissues, leading to a state of lipotoxicity and related disease states. 
Modified from [7] 	  
Fatty acids uptake and metabolism 
Fatty acids are vital molecules that are important for the metabolic homeostasis and 
normal human physiology [8]. Fatty acids, especially long chain fatty acids (LCFA) serve 
various functions in the human body which includes usage or storage as fuel for energy 
Systemic Inflammation 
Increased cytokine release 
Fatty Acid oxidation 
ROS accumulation 
Ceramide accumulation 
ER stress response 
Organellar dysfunction 
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production, precursors of complex membrane lipids, signaling molecules and as ligands 
for various transcription factors [9, 10].  
Modes of fatty acid uptake 
Non-protein mediated uptake of fatty acids 
There has been a considerable debate over the mechanism of FA uptake into the cells and 
it is not yet completely understood [10, 11]. Earlier studies suggested that FA could 
passively diffuse through the plasma membrane and this may occur at a region of high 
fatty acid concentration. The two major factors governing the passive uptake of fatty 
acids are the molar ratio of fatty acid to albumin in circulation and cellular FA 
metabolism [11]. 
 
The transport of FA into cells minimally involves three steps: adsorption, transmembrane 
movement and desorption. For adsorption to take place, the FA must be in its free form 
and not bound to albumin. The portioning of FA between albumin and plasma membrane 
is dependent on various factors that include the type of FA, saturation of FA and FA to 
albumin ratio. In addition, the membrane composition and localized pH may also 
influence. This FFA, now separated from albumin, then adsorbs to the outer leaflet of 
plasma membrane; orients its carboxyl head group to the cytosolic side during 
transmembrane movement and finally desorbs to the cytosolic inner side of plasma 
membrane where it is utilized for downstream functions [12, 13]. Thus, the non-protein 
mediated uptake of fatty acids by diffusion requires the flip-flop of charged head group 
from one side of the membrane to other. The kinetic studies supporting diffusion process 
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suggest that the rate of uptake via non-protein mediated process is slow and uniform in 
all cell types [12, 14]. 
 
Protein-mediated uptake of fatty acids 
However, it is also true that the uptake of fatty acid is highly regulated in different 
physiological and pathophysiological states [12]. A constant flux of FA is maintained 
depending on their demand, and uptake varies especially in metabolically active tissues 
such as heart, skeletal muscle or adipocytes [10]. Various studies have also depicted that 
binding and flipping of the fatty acid across the transmembrane is very fast and exhibit 
saturable kinetics, thus pointing towards the involvement of carrier proteins [12, 14]. 
Secondly, studies using fluorescent fatty acid binding protein (ADIFAB) have allowed 
evaluation of unbound fraction of fatty acids in circulation. Under a normal physiological 
state, FA transfer to membranes is limited by binding of FA to albumin (FA: albumin 
ratios of 0.25-1). However, FA needs to be in an unbound form to be taken up by cells. If 
a facilitated mechanism of uptake were absent, the efflux of fatty acid to albumin-
containing medium would occur. Thus, as per the current understanding, the proteins 
involved in the movement of fatty acids across the membrane are likely to be involved in 
the delivery of fatty acids to the membrane, the transmembrane movement of anionic 
fatty acid from one leaflet to other, and removal of fatty acids from the membrane for 
downstream metabolism. All these considerations, thus, provide a rationale for facilitated 
transport under physiological conditions [8, 11, 15, 16].  
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Evidence of Protein-mediated fatty acid transport  
The presence of transport proteins for the import of fatty acids is well documented and 
evidenced in prokaryotes and eukaryotes. Bacterial [17] and yeast [18] fatty acid 
transport proteins are well studied and reviewed [14, 19], however here we will only 
discuss proteins involved in mammalian fatty acid transport.  
 
Mammalian Fatty acid transport 
Several proteins have been proposed to participate as fatty acid transport proteins in the 
mammalian system. Fatty Acid Translocase (FAT/CD36), Fatty Acid Binding Protein-
plasma membrane bound (FABPpm) and Fatty Acid Transport Protein (FATP) -are the 
major proteins proposed to be involved in exogenous fatty acid uptake [8].The key 
features of these transport proteins along with their role in lipid metabolism and 
pathophysiology is detailed below. 
 
Cluster of Differentiation (CD36)/Fatty Acid Translocase (FAT) 
CD36, also known as fatty acid translocase (FAT) is the first eukaryotic fatty acid 
transport protein to be identified. It is an 88kDa transmembrane glycoprotein identified 
for its ability to bind the FA analog sulfo-N-succinimidyl-oleate (SSO) and the anion 
inhibitor 4,4’-diisothiocyanostilbene-2,2’-disulfonate (DIDS). CD36/FAT belongs to the 
class B scavenger receptor family and occurs in various cell types such as macrophages, 
microvascular endothelial cells, cardiomyocytes, adipocytes and skeletal muscle cells. In 
addition to be involved in binding and uptake of long chain fatty acids (LCFA), it also 
acts as a receptor for thrombospondin-1, modified low density lipoprotein (LDL), 
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Plasmodium falciparum malaria-parasitized erythrocytes and anionic phospholipids [12, 
14]. Studies involving cultured fibroblast have shown that over-expression of CD36/FAT 
results in saturable uptake and utilization of LCFA. In-vivo studies involving gain and 
loss of function have provided evidences for the role of CD36/FAT in fatty acid 
metabolism. Overexpression of CD36/FAT in mice have shown increased fatty acid 
oxidation in tissues specifically muscle, leading to a leaner body mass and reduced levels 
of triglycerides in blood. On the other hand, loss of CD36/FAT in spontaneously 
hypertensive rats (SHR) is associated with hypertriglyceridemia, hyperinsulinemia and 
may even lead to hypertropic cardiomyopathy [16]. Other studies have shown that mice 
with CD36/FAT gene deleted are viable though they have significantly reduced ability to 
bind and uptake oxidized LDL, have increased fasting levels of cholesterol, non-
esterified fatty acids and triglycerides (LDL fractions). This suggests that CD36/FAT 
functions in concert with other transport proteins for binding and uptake of LCFAs [10, 
14]. 
 
Fatty Acid Binding Protein-plasma membrane bound (FABPpm) 
Plasma membrane bound Fatty Acid Binding Protein (FABPpm) was first isolated by 
oleate-agarose affinity chromatography from rat hepatocytes by Stremmel et al. [16, 20]. 
It is a 40kDa protein identical to mitochondrial aspartate aminotransferase and is 
expressed in distinct tissues including liver, heart, adipose tissue and small intestines. The 
evidence for the involvement of FABPpm in fatty acid transport comes from the studies 
showing the inhibition of fatty acid uptake in the presence of antibodies targeted against 
FABPpm in hepatocytes, jejunal microvilli, adipocytes, cardiomyocytes and cardiac and 
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skeletal muscle-derived giant vesicles. However, the inhibition was incomplete (50%) 
[21]. This protein is also induced during differentiation of 3T3-L1 cells and its expression 
was associated with increased FA uptake. Overexpression studies have shown that 
FABPpm overexpression in skeletal muscle did not affect the triglyceride formation but 
increased fatty acid oxidation [21]. In another study, it was shown that the treatment of 
intestinal cells, which express FABPpm, with anti-FABPpm sera did not inhibit long 
chain fatty acid uptake. Thus the role of FABPpm in LCFA transport is still controversial 
[14, 16, 22].  
  
Fatty Acid Transport Proteins (FATPs) 
Fatty acid transport proteins (FATP) are the members of solute carrier family 27 (SLC27) 
comprising six members-SLC27A1-6, encoding FATP1-6 [23]. These are 63-80kDa 
proteins with at-least one transmembrane region/domain. All FATPs have a signature 
sequence of 311 amino acids, known as the FATP sequence, which is highly conserved 
and is centrally located on the C-terminus [23, 24]. All the members of this family are 
evolutionarily conserved and share remarkable homology among themselves as well as 
within species. Six humans and murine FATPs have been identified so far. Other than 
mammals, Drosophila melanogaster, Caenorhabditis elegans, Saccharomyces cerevisiae 
and Mycobacterium tuberculosis also have FATPs. Yeast FATP orthologue, Fat1p, has 
35% homology with Mus musculus FATP1 (mmFATP1) and mmFATP4. Two regions 
within these proteins are about 70-80% identical- the ATP/AMP binding domain; and 
FATP-VLACS (very long chain acyl-CoA synthetase) motif (Figure 1B) [24]. The 
FATP-VLACS motif is thought to contribute to the fatty acid binding whereas the 
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sequence identity within the ATP/AMP motif is known to be shared with a superfamily 
of adenylate-forming enzymes including fatty acyl CoA synthetase (FACS) [25]. FACS 
catalyzes the formation of fatty acyl CoA through a two-step process by forming fatty 
acyl AMP intermediate as shown in the equation below: 
Fatty acid + ATP             fatty acyl-AMP + PPi 
Fatty acyl-AMP + CoA            fatty acyl-CoA + AMP 
 
This reaction follows Bi Uni Uni Bi Ping-Pong mechanism in which the fatty acid is 
activated by binding of the carboxyl group of fatty acid to the phosphoryl group of AMP 
and releasing a pyrophosphate. Finally, transfer of fatty acyl-AMP to the sulfhydral group 
of CoA generates fatty acyl CoA and releases AMP. Thus, the activated fatty acid is used 
for downstream metabolic activities such as complex lipid synthesis, fatty acid oxidation 
and so on. This concomitant transport and activation of fatty acid is known as vectorial 
acylation [14]. Evidence of vectorial acylation comes from bacterial [17] and yeast [18, 
26] fatty acid transport. Specifically directed mutagenesis studies [18] in yeast have 
distinguished the fatty acid transport from activation, further providing evidence that 
FATPs are bi-functional proteins involved in import as well as activation of fatty acids. 
 
In mammalian system, the expression pattern (Figure 1C), tissue distribution and 
subcellular localization of FATPs are quite varied. The first FATP (FATP1) was 
identified using an expression cloning technique from 3T3-L1 adipocyte cDNA library. 
Heterologous expression of the protein increased the saturable uptake of LCFA, thus 
suggesting the role of FATP in transport of fatty acids across membrane. 
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Figure 1B: Domain organization of FATP family of proteins. Top panel: Amino acid 
sequence alignment of ATP-AMP motif and FATP/VLACS motif from Fat1p and six murine 
orthologues of FATP. Bottom panel: Approximate positions of the two motifs in FATP family of 
proteins. aa, amino acids [14]. 	  	  
	  
Figure 1C: Tissue specific expression of different FATPs in mammals. The level of 
expression of specific FATP decrease with the reduction in the font size of FATP [23]. 
 
 
in long-chain fatty acid uptake, although the protein was de-
tected (57).
Fatty Acid Transport Protein
In 1992, two mouse proteins were identified using expres-
sion-cloning techniques, which, following transfection of Cos7
cells, resulted in an increased level of fluorescent fatty acid
accumulation. The first was FATP, and the second was FACS
(see below) (115). The use of expression cloning demonstrated
a direct physiological role for both of these proteins in the net
accumulation of fatty acids across a biological membrane. A
number of different isoforms of FATP have subsequently been
identified experimentally in mice, rats, humans, and yeast (e.g.,
mmFATP1, through mmFATP6 in mice) (54, 61, 74, 119–121).
Members of the FATP family have also been identified exper-
imentally or by sequence comparisons in nonmammalian sys-
tems including Caenorhabditis elegans, Drosophila melano-
gaster, S. cerevisiae, and M. tuberculosis (54, 74). The first
mouse isoform identified (mmFATP1) has 646 amino acid
residues and an apparent molecular weight of 63,000. Hydrop-
athy profiles predict that mmFATP1 contains one to four
membrane-spanning segments; recent experiments employing
epitope tagged forms have confirmed the presence of at least
one transmembrane domain (95). Immunofluorescence studies
of epitope-tagged mmFATP1 support the prediction this is an
integral membrane protein localized, at least in part, to the
plasma membrane (95).
The yeast FATP orthologue, Fat1p, has 35% sequence iden-
tity to mmFATP1 and mmFATP4 (50, 54, 74). Fat1p, like
several mmFATP isoforms, plays a role in the transport of
long-chain fatty acids across the plasma membrane and in the
activation of very long-chain fatty acids (36, 50, 136). Two
subdomains within these proteins, in particular, have a signif-
icant level of identity (70 to 80%), which serves as distinguish-
ing sequence elements or motifs (Fig. 2): (i) the ATP-AMP
binding motif (common to all adenylate-forming enzymes) and
(ii) the FATP-VLACS motif, which may be involved in con-
tributing to fatty acid specificity (and generally is restricted to
the FATP and very long-chain acyl-CoA synthetase [VLACS]
families). Some sequence identities within these motifs (par-
ticularly the ATP-AMP motif) are also shared among the
greater superfamily of FACSs (see below). The finding these
proteins belong to the superfamily of adenylate-forming en-
zymes was noted in the initial characterization of Fat1p, which
suggested an enzymatic activity (54). Indeed, subsequent stud-
ies have demonstrated that increased expression of three iso-
forms of the murine FATP (mmFATP1, mmFATP2, and
mmFATP4) and yeast Fat1p results in increased VLACS ac-
tivities (36, 38, 50, 71, 72, 136, 140). Data from the Schaffer
laboratory has shown an mmFATP1 allele carrying a single
amino acid substitution in the predicted ATP-AMP binding
region fails to transport fatty acids (127, 128). One interpreta-
tion of these data is that the formation of an acyl-adenylate
intermediate is required for transport.
The Long-Chain Fatty Acid Transport Protein FadL
Of the proteins characterized to date, only the long-chain
fatty acid transport protein FadL, found in gram-negative bac-
teria, fulfills all the criteria that defines an integral membrane-
bound fatty acid transporter. (i) FadL is localized in the outer
membrane, where it is proposed to span the membrane 20
times and form a !-barrel specific for the transmembrane
movement of long-chain fatty acids (42). (ii) Bacterial strains
with a deletion of the fadL gene cannot grow on long-chain
fatty acids as a sole carbon and energy source and cannot
transport long-chain fatty acids across the cell envelope, yet
FIG. 2. Domain organization of the FATP family of proteins. (A) Amino acid sequence alignments of the ATP-AMP motif (common to all
members of the adenylate-forming superfamily f enzymes) and the FATP-VLACS motif (restric d to the FATP family) from Fat1p and the six
murine FATP orthologues. (B) Cartoon showing the approximate positions of the two elements of the ATP-AMP (white rectangles) and the
FATP-VLACS (black rectangle) motifs in the FATP family of proteins. aa, amino acids.
458 BLACK AND DIRUSSO MICROBIOL. MOL. BIOL. REV.
activity, these mutations also led to decreased LCFA uptake, suggesting that FATPs are involved in both fatty acid activation
and uptake (Choi and Martin, 1999; Coe et al., 1999; Watkins et al., 1998).
Interestingly, both the yeast and murine forms of FATP1 and ACSL-1, a member of the acyl-CoA synthetase long-chain
family, may interact with each other to form a complex (Richards et al., 2006; Zou et al., 2003). Inhibition of ACSL-1 impaired
LCFA uptake, suggesting that fatty acid activation is crucial for LCFA uptake and that the interaction of FATP1 and ACSL-1 is
responsible for LCFA uptake (Richards et al., 2006). Furthermore, overexpression of FATP4 in cells led to increased ACS activ-
ity, and mice lacking FATP4 had reduced LCFA activation in the skin and intestine (Hall et al., 2005; Herrmann et al., 2001).
The findings that FATPs have intrinsic ACS activity, together with studies demonstrating the direct role of FATPs in LCFA up-
take, support the notion of vectorial acylation, in which LCFA transport is directly coupled to fatty acid activation (Black and
DiRusso, 2007a).
3.3. Subcellular localization of FATPs
Studies examining the subcellular localization of FATPs have supported a role for the proteins in both fatty acid uptake as
well as activation. FATPs can reside in both the plasma membrane as well as the intracellular space. FATP1 was first iden-
tified as an integral membrane protein that localizes to the plasma membrane (Schaffer and Lodish, 1994). FATP4 is localized
only to the apical side of intestinal enterocytes, where it is associated with the plasmamembrane (Stahl et al., 1999). Another
study demonstrated the presence of FATP4 in the ER of intestinal enterocytes (Milger et al., 2006). The differences in FATP4
Fig. 1. Protei structure o FATP1. Structur d mains of FATP1 are listed on the right. Locations of the domains within FATP1 are indicated by amino acid
residue number. ⁄ER localization domain has been identified only in FATP4.
Fig. 2. FATP expression pattern in vivo. Relative expression levels of FATPs in mammalian tissues are depicted. Increasing font size corresponds to greater
expression levels. ⁄FATP5 is expressed only in the liver and FATP6 is expressed almost exclusively in the heart. #Relative expression level of each FATP in
endothelial cells has not been determined.
C.M. Anderson, A. Stahl /Molecular Aspects of Medicine 34 (2013) 516–528 519
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Along with FATP1, another gene encoding FACS (Acsl1) was identified and was 
suggested to work in concert with fatty acid transport protein for activation of fatty acids 
as evident in bacterial and yeast systems. Initially the other protein (Acsl1) was largely 
ignored, but later it was shown to work in concert with FATP to facilitate the movement 
of LCFAs across the plasma membrane by co-ordinate uptake and activation with 
coenzyme A (CoA) [27-29]. Subsequently, four other isoforms, FATP2-6, were 
discovered [23].  
 
FATP1 
Various studies have been done to understand the role of FATP family members in 
transport and activation of fatty acids. The first isoform of the FATP family, FATP1, is a 
646 amino acid integral plasma membrane protein highly expressed in skeletal muscle, 
adipocytes and heart. In-vitro studies on 3T3-L1 adipocytes revealed the hormonal 
regulation of FATP1 by insulin. Insulin does not affect FATP1 expression, rather it 
causes the translocation of FATP1 to plasma membrane thereby increasing LCFA uptake 
[23]. Further, treatment of 3T3-L1 adipocytes with TNF-alpha to inhibit insulin action 
reverses FATP1 activity and thus LCFA uptake [23, 30]. Gain/loss of function studies of 
FATP1 suggests its contribution to insulin resistance and energy expenditure. FATP1 null 
mice are protected against the accumulation of fatty acid derived metabolites during high 
fat feeding and do not develop insulin resistance in skeletal muscle [31]. Another role of 
FATP1 was observed in non-shivering thermogenesis in brown adipose tissue (BAT). In 
control animals, an increase in LCFA uptake is observed in response to cold stimuli. 
However, when null animals are subjected to cold, a decrease in intracellular lipid 
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droplets in BAT was observed thus resulting in an inability of the animal to adapt to cold 
stress. This further establishes the role and importance of LCFA uptake by FATP1 in 
non- shivering thermogenesis [24, 32].  
 
FATP2 
Small intestine [33], liver and kidney are known to be the major sites of FATP2 
expression. Trophoblasts of the human placenta express low levels of this FATP [23, 34]. 
Along with FA transport, FATP2 is also known to have very long chain acyl-CoA 
synthetase (VLACS) activity [35]. Recently two splice variants of this protein have been 
identified in humans- FATP2a and FATP2b (Figure 1D) [33]. Both of the isoforms can 
transport FA but only FATP2a has ACS (acyl-CoA synthetase) activity specific for 
VLCFA. The ACS activity of FATP2b is lost due to the elimination of amino acids 
critical to ATP binding [33]. Genetic studies in mice have confirmed both the activities of 
FATP2. In a study in which liver-specific adeno-associated virus (AAV) based 
knockdown of FATP2 was carried out, protection from diet-induced hepatosteatosis was 
observed by improved insulin sensitivity and glucose homeostasis [35]. Knockdown of 
FATP2 in liver also exhibited slight reduction in overall VLACS activity however a 51% 
reduction in the peroxisomal VLACS activity was measured. This suggests the presence 
of another ACS in the liver peroxisomes that carries out the remaining ACS activity after 
FATP2 knockdown [35].  
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Figure 1D: Tissue specific expression of FATP2 variants- FATP2a and FATP2b determined 
using RT-PCR in placenta (P), liver (L), brain (B), heart (H), colon (C), small intestines (I), white 
adipose tissue (A) and kidneys (K). Arrows indicate the positions of FATP2a and FATP2b bands 
corresponding to the controls in lane 1 and 2 [33]. 
 
 
FATP4 
FATP4 is expressed in small intestines, adipose tissue and skeletal muscle with relatively 
low expression in brain, kidney, liver and skin. It is 60% homologous to FATP1. 
Overexpression of FATP4 led to increased LCFA uptake and knockdown of FATP4 gene 
in isolated enterocytes reduced LCFA uptake [36]. Many groups have also generated 
FATP4 null mice; however, these mice show features of restricted dermopathy and die 
embryonically or perinatally because of rigid and thickened skin, flexion contracture and 
severe inability to breathe and suckle [37, 38]. These animals also have ineffective skin 
barrier to prevent dehydration and an altered lipid composition [23, 37]. These features 
could be rescued when FATP4 was overexpressed in a keratinocyte-specific manner, thus 
confirming the role of FATP4 in skin and hair development [39]. Shim et al. studies on 
FATP4 transgenic mice driven by keratinocyte-specific promoter suggests that these mice 
are not protected against high-fat diet induced weight gain and thus other mechanisms 
may be involved in FA uptake in intestine making FATP4 dispensable/optional for lipid 
transport [40]. Instead, an additional role of FATP4 as an ACS has been proposed. Over-
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expression of FATP4 in cells has been shown to increase long chain and very long-chain 
acyl-CoA synthetase activity, thus supporting its role as an acyl-CoA synthetase [41].  
 
The role of FATP3, FATP5 and FATP6 in transport of fatty acids is still questionable. 
When murine transport proteins (mmFATP1-6) were expressed in yeast, FATP3, 5 and 6 
did not complemented the deficiency of yeast Fat1p knockout strain in fatty acid 
transport. FATP 3 and 6 gave synthetase activity but FATP 5 did not [42].   
 
FATP3 
Additional studies have shown that mouse orthologue of FATP3 protein is expressed in 
adrenal glands, testis, ovary and lungs. It is also weakly expressed in neonatal and adult 
brain, but highly expressed in embryonic brain [23, 24]. There is strong evidence that this 
protein is a peroxisomal VLACS and does not exhibit transport activity [43].  
 
FATP5 
FATP5 is expressed in liver where it is proposed to both facilitate FA transport and the 
esterification of bile acid with CoA. Studies with FATP5 knockout mice exhibit lowered 
triglyceride and fatty acid levels in liver and also an increased fatty acid synthase 
expression. Further studies revealed the redistribution of fatty acids from liver to other 
fatty acid metabolizing tissues in knockout mice. Knockdown studies of FATP5 have 
also established its protective role against non-alcoholic fatty liver disease (NAFLD). In 
another study, a rat orthologue of FATP5 is shown to have bile-CoA ligase activity, thus 
catalyzing the conjugation of bile acids with glycine and taurine [23, 24, 44].  
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FATP6 
The last isoform, FATP6 has been described as a heart-specific fatty acid transport 
protein [45]. It is localized in the sarcolemma of cardiomyocytes and plasma membrane 
juxtaposed to the blood vessels of heart. It has been shown to function as a transport 
protein in rats. In this model, cardiac infarction was associated with reduced FATP6 and 
FATP1 expression, and also correlated with reduced lipid oxidation and incorporation. 
However, the precise role of FATP6 in FA transport and activation is still not clear. The 
whole body or tissue specific knock out of FATP6 in animals have not been generated 
[23].  
 
Since the discovery of FATPs and their role as transport proteins, significant progress has 
been made in understanding the role of these protein in the pathophysiology of diseases 
ranging from dyslipidemia to lipotoxicity to hepatosteatosis to cardiomyopathy. 
However, very few studies have targeted the uptake of fatty acids as therapeutic 
interventions to reduce the disease conditions. Drugs either in use or in development are 
directed towards [i] targeting weight gain (e.g. orlistat), [ii] insulin resistance (e.g. 
metformin and thiazolidinedione’s), or [iii] dyslipidemia (e.g. statins and fenofibrate). 
Side effects due to these compounds such as myopathy, gastrointestinal effects, fluid 
retention etc. are also well documented and raise concerns of their clinical utility [46]. 
Pharmaceutical interventions are needed that more narrowly target the involved 
metabolic pathways and limit deleterious side effects. 
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The research proposed here is targeted towards characterizing newly identified fatty acid 
uptake inhibitors, CB5/Grassofermata and CB16.2/Lipofermata [47] that inhibit uptake of 
fatty acids in a FATP2-mediated manner. We propose that these compounds are useful to 
understand the role of fatty acid uptake and accumulation in normal cellular homeostasis, 
as well as in lipotoxicity, which contributes to cardiomyopathies, insulin resistance and 
additional organellar dysfunction.   
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SPECIFIC AIMS 
Small molecule inhibitors CB5/Grassofermata (2-benzyl-3-(4-chlorophenyl)-5-(4-
nitrophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one)  and CB16.2/Lipofermata (5’-bromo-5-
phenyl- spiro[3H-1,3,4-thiadiazole-2,3’-indoline]-2’-one) [47] were identified during a 
high throughput screening in humanized yeast [48]. Previous studies from our lab have 
shown that these compounds inhibit fatty acid uptake in low micro-molar ranges; are not 
toxic to cells in culture; and do not affect transport of other molecules. Ongoing studies in 
our lab and the research presented here investigate the role of CB5, in different cell 
culture models; examine the pharmacokinetics of CB5 and CB16.2; and present 
preliminary animal studies for these small molecule inhibitors. Cell culture studies related 
to CB16.2 are reported separately [47]. 
 
The specific aims of the proposed research are detailed below and presented graphically 
in Figure 1E: 
 
Aim 1: Evaluate the activity of CB5/Grassofermata as an inhibitor of FATP2-mediated 
fatty acid uptake in mammalian cell lines that are models for muscle (C2C12), pancreatic 
β-cell (INS-1E) and human adipocytes and further demonstrate its ability to protect 
against lipotoxicity generated by a saturated fatty acid. 
 
Aim 2: Evaluate the pharmacokinetic properties of FATP2-mediated fatty acid uptake 
inhibitors (CB5/Grassofermata and CB16.2/Lipofermata) in-vitro and in-vivo.  
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Aim 3: Evaluate the effects of high fat and low fat diets on a whole body knockout of 
FATP2 gene in 129S mice. This study is important to understand the effect of whole 
body FATP2 knockout in vivo with diets varying in the amount of fat prior to correlating 
with studies using inhibitors in animal models. 
 
	  
Figure 1E: Specific aims of the research proposal. Aim 1: Evaluation of CB5 for uptake 
inhibition of fatty acids and ability to protect from lipotoxicity in different cell lines. Aim 2: 
Pharmacokinetic analysis to CB5 and CB16.2 in vitro and in vivo. Aim 3: Evaluate the 
implications of diet on whole body FATP2 knockout and wild type mice.  
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CHAPTER 2 
 
 
 
 
 
FATTY ACID TRANSPORT PROTEIN-2 MEDIATED FATTY ACID UPTAKE 
INHIBITOR CB5/GRASSOFERMATA (2-BENZYL-3-(4-CHLOROPHENYL)-5-(4-
NITROPHENYL)PYRAZOLO[1,5-A]PYRIMIDIN-7(4H)-ONE) PROTECTS 
AGAINST LIPOTOXICITY AND CELL DEATH. 
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ABSTRACT 
Inhibition of uptake of fatty acids in non-adipose tissues seems an attractive mechanism 
for treatment of lipotoxicity, dyslipidemia and other elements related to metabolic 
syndrome and obesity. Fatty acid transport proteins (FATPs) are bifunctional proteins 
involved in the uptake and activation of fatty acids by esterification with coenzyme A. To 
date, only inhibitors specific to FATP1 and FATP4 have been identified. Here we 
characterize a FATP2-specific fatty acid uptake inhibitor, CB5. Identified in a high 
throughput screening in yeast transformed with humanFATP2, CB5 is effective in 
inhibiting the uptake of fatty acid at low micro-molar ranges in cell lines that are models 
for intestines, liver, muscle, pancreas and adipose tissue with varying potencies. 
Inhibition was also specific for long and very-long chain fatty acids and not for medium 
chain fatty acids, which are transported by diffusion. Finally, CB5 was effective in 
protecting the cell lines that are models for liver and pancreas and primary liver cells 
from lipotoxic effects of saturated fatty acid, palmitic acid. High throughput screening 
also identified clozapine and chlorpromazine, atypical antipsychotics drugs, as inhibitors 
of FATP2-mediated fatty acid uptake in yeast system. However, atypical antipsychotics 
were ineffective in inhibiting the uptake of FA-analog C1-BODIPY-C12 in HepG2 cells. 
They were also ineffective in protecting HepG2 cells from the lipotoxic effects generated 
by saturated fatty acid compared to CB5 that exhibited protection to the cells, 
demonstrating that they are not effective inhibitors of fatty acid transport compared with 
CB5.
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2.1. INTRODUCTION 
Obesity is a multifactorial, chronic disorder that is associated with constellation of 
diseases including, but not limited to, hyperlipidemia, insulin resistance, diabetes 
mellitus, hypertension and cardiovascular diseases [49]. Chronically elevated level of 
fatty acids in systemic circulation are considered major contributing factors to the 
development of these diseased states [50]. An overflow and over-accumulation of 
unoxidized long chain fatty acids causes saturation in the storage capacity of the adipose 
tissue resulting in a “spill-over” of fatty acids in circulation resulting in deposition in 
non-adipose tissues such as liver, heart, pancreas and muscles that have a limited capacity 
to store fats. This ectopic accumulation of fat in non-adipose tissues causes deleterious 
effects and leads to cellular dysfunction and organ failure, a state called lipotoxicity, 
resulting in programmed cell death, known as lipoapoptosis [50, 51].  Thus, targeting and 
inhibiting the uptake of fatty acids into the cells are suggested as possible therapeutic 
solutions to this rising pandemic.  
 
Long Chain Fatty Acids (LCFAs) are vital components for various processes in the body 
including usage and storage as fuel for energy, precursors for complex membrane lipids, 
ligands for transcription factors and as signaling molecules [9, 10, 23, 24]. The transport 
of fatty acids across the cell membrane is concomitant with their activation to CoA 
thioesters via vectorial acylation and required for metabolic utilization of fatty acids [8]. 
The mechanism(s) of uptake of fatty acids is not yet completely understood, however, 
experimental evidence supports the presence of both protein mediated and diffusional 
uptake of fatty acids. The non-protein mediated uptake of fatty acids by diffusion requires 
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the flip-flop of charged head group from one side of the membrane to other [12]. In the 
recent past, ample evidence has been put forth to support the protein mediated uptake of 
fatty acids [10, 34]. Various studies have demonstrated that binding and transmembrane 
flip of fatty acid is faster than could occur by diffusion and exhibits saturable kinetics, 
thus supporting the involvement of carrier proteins [12, 14]. Several candidate proteins 
have been implicated in the saturable uptake of exogenous long chain fatty acids into the 
cells. Plasma membrane Fatty Acid Binding Protein (FABPpm), the scavenger receptor 
CD36 (Fatty Acid Translocase-FAT), Fatty Acid Transport Proteins (FATPs) and Long-
Chain Acyl CoA Synthetase (ACSL) are the best characterized among these [8, 14, 24, 
34] (These are detailed in Chapter 1). 
 
The role of transport proteins as regulators of lipid metabolism is of great interest 
specially in understanding the pathophysiology of various diseases such as dyslipidemia, 
lipotoxicity, cardiomyopathy and so on [21]. However, very few studies have targeted the 
protein-mediated uptake of fatty acids as therapeutic interventions to reduce the disease 
conditions. FATP1 and FATP4 inhibitors have been reported, however, these inhibitors 
were screened on the basis of inhibition of long-chain acyl CoA synthetase activity rather 
than the transport activity and were not effective in animals [52-54]. In order to 
understand the linkage and role of FATPs in the excessive accumulation of fat in various 
diseased states, Sandoval et al., 2010 [48] utilized a high-throughput screening assay [55] 
in yeast transformed with human FATP2 to screen library for inhibitors of fatty acid 
uptake. This led to the identification of 2-benzyl-3-(4-chlorophenyl)-5-(4-
nitrophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one, also known as CB5 or Grassofermata. 
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CB5 was shown to be capable of inhibiting the uptake of FA-analog C1-BODIPY-C12 
using a live cell based assay in yeast as well as mammalian cell lines that are models for 
liver, small intestines and adipose tissue (HepG2, Caco-2 cells and 3T3-L1 adipocytes, 
respectively) [48]. In another HTS of 2000 compounds [56], compounds structurally 
related to phenothiazine group were identified as inhibitors of FA uptake. This included 
the atypical antipsychotics, chlorpromazine and clozapine as hits. Both compounds at 
80µM concentration when tested in yeast cells caused intermediate levels of inhibition of 
FA- analog C1-BODIPY-C12 [56]. Thus it was predicted that dyslipidemia caused by 
these antipsychotics is due the mechanism involving the inhibition of FA uptake using 
FATPs. 
 
In the current study, we have further characterized CB5 for its activity as an inhibitor in 
various cell lines that are models for pancreatic islets, muscles and human adipocytes. 
CB5 inhibition was specific for long and very long chain fatty acid and was protective 
against lipotoxicity caused by saturated fatty acids. We also compared the inhibition 
activity of AAP drugs to CB5 and show that their mechanism of action in causing 
dyslipidemia is different from inhibition of FA uptake and thus do not involve FATPs.  
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2.2. RESULTS 
2.2.1 Kinetics of C1-BODIPY-C12 in different cell lines 
The Kinetics of transport of C1-BODIPY-C12 was determined in HepG2, Caco-2, INS-1E, 
C2C12 and human adipocytes. This was done to monitor the transport of fatty acids in 
mentioned cell lines in real time using an assay previously described by our lab [57]. As 
shown in Figure 2.1, the transport of FA-analog C1-BODIPY-C12 follows a typical 
Michaelis-Menton kinetics. The accumulation of FA-analog was least efficient in INS-1E 
cells. These cells had a Vmax of 17.1±1.5 µmol/min/106 cells which was 2.4-fold lower 
than muscle cell line C2C12, 4-fold lower than Caco-2 and HepG2 cells, and 32-fold 
lower than human adipocytes. The KT values were more similar in all the cell lines (Table 
2.1) tested which suggests that affinity for fatty acids may be equivalent between the cell 
lines but the uptake and storage capacity is variable.  
 
2.2.2 Inhibition of C1-BODIPY-C12 uptake in C2C12, INS-1E and human adipocytes 
CB5 was identified as a FATP2-mediated FA uptake inhibitor in a high throughput 
screening (HTS) of chemical compounds in humanized yeast. Further testing of CB5 in 
HepG2 and Caco-2 cells, models for liver and small intestines, confirmed the role of CB5 
as an inhibitor of fatty acid uptake [48]. However, the process of fatty acid metabolism is 
also interlinked with muscle and fat metabolism. Additionally, pancreatic control of 
glucose homeostasis is coordinated with regulation of FA metabolism and pancreatic β-
cells are particularly sensitive to FA-mediated lipotoxicity [58]. The action or effect of 
changes on one tissue/organ, affects the nearby tissues in one way or another. To test the 
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Figure 2.1: Kinetics of C1-BODIPY-C12 in specified cell lines. Fatty acid transport was 
measured in real-time using C1-BODIPY-C12 (0-100μM) at 5 sec intervals for 5 min. The linear 
rate of uptake for each concentration of fluorescent fatty acid was determined using initial values 
from 30 to 90 sec and plotted as μmol/min/106 cells ±standard error (n=3). The Vmax and KT 
values for all cell lines are detailed in Table 2.1. (**Zhigang Wang, research technician, assisted 
completion of these experiments.)  
 
 
Table 2.1: Kinetic parameters of C1-BODIPY-C12 transport in different cell lines. The values 
are represented as ± standard error. The details of the experiment are explained in the legend of 
Figure 2.1.  
Cell Line Vmax (µmol/min/106 cells) KT (µM) 
HepG2 67.3±6.6 40.1±8.7 
Caco-2 63.5±5.8 32.8±7.1 
C2C12 40.1±1.9 20.9±2.6 
INS-1E 17.1±1.5 18.1±4.3 
Human Adipocytes 559.2±57.5 43.7±9.7 
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Figure 2.2: Dose response curves of C1-BODIPY-C12 inhibition by CB5 in A) HepG2 cells, B) 
Caco-2 cells, C) C2C12 cells, D) INS-1E cells, and E) Human Adipocytes. Curves were fit using 
dose-response non-linear regression model in Prism 5.0 software. Values are expressed as ± SE 
for 3 experiments done in triplicates. 	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sensitivity of different model cell lines to CB5, we compared the inhibition activity of 
CB5 in C2C12, INS-1E and human adipocyte cell lines, models for muscle, pancreatic β-
cells and adipose tissues. CB5 was effective in inhibiting the uptake of FA analog C1-
BODIPY-C12 in C2C12 and INS-1E (FATP2 expressing cell lines [47]) cells with IC50s 
of 10.6 and 8.3µM, respectively (Figure 2.2). On the other hand, the half-maximal 
inhibition value (IC50) was much higher in human adipocytes (58.2µM). This is almost 6-
fold higher than HepG2 cells and 9-fold higher than Caco-2 cells that express FATP2 at 
high concentrations [47, 48]. Furthermore, CB5 inability to inhibit uptake of FA analog 
BODIPY in human adipocytes is at advantage because it is a store house of fat and we 
expect it to store maximum fat which is re-routed from other non-adipose tissues such as 
liver, muscle and pancreas. 
 
2.2.3 Examination of CB5 activity in inhibiting uptake of fatty acids with different 
chain lengths 
To assess the inhibitory effect of CB5 against transport of FA with different chain length, 
we employed BODIPY FL-C5, a medium chain FA- analog and BODIPY FL-C16, a very 
long chain FA-analog in studies employing HepG2 and Caco-2 cell lines. Medium chain 
length fatty acids (C6-C10) are transported into the cells via diffusion whereas protein-
mediated processes are required for transport of long chain and very long chain fatty 
acids. Our data demonstrated that the uptake of medium chain FA-analog was not 
saturable and exhibited a protein-independent mechanism of uptake [47]. However, the 
uptake of very long chain FA-analog was saturable and displayed a typical Michaelis-
Menton kinetics [47]. CB5 was effective in inhibiting the uptake of BODIPY FL-C16 in 
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HepG2 (Figure 2.3A) and Caco-2 cells (Figure 2.3B) with IC50 values of 17.0±2.5µM and 
13.5±1.1µM, respectively. As expected, CB5 did not affect the transport of BODIPY FL-
C5 in either of the cell lines since the uptake of small and medium chain fatty acids occur 
via simple diffusion [10]. 	  
 
 
 
 
Figure 2.3: Inhibition of FA-analog BODIPY FL C5 and BODIPY FL C16 by CB5 in A) 
HepG2, and B) Caco-2 cells. Curves were fit using dose-response non-linear regression model in 
Prism 5.0 software. Values are expressed as mean ± SE for 3 experiments assayed in triplicate. 
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2.2.4 CB5 protects against lipotoxicity induced by saturated fatty acids  
Saturated free fatty acids, particularly, palmitic acid are known to induce lipotoxicity and 
apoptosis in various cell lines [59]. We predicted CB5 would be protective against 
palmitate-mediated lipotoxicity. Therefore, HepG2, INS-1E cells (model for liver and 
pancreatic β-cells) and freshly isolated primary hepatocytes from 129S1/SvImJ mice 
were treated with varying concentrations of palmitic acid (0-500µM) without or with 
CB5 (5-50µM). As the concentration of PA increases, lipid accumulation increases in a 
dose dependent manner (Figure 2.4A: HepG2 cells; Fig 2.5A: Primary hepatocytes and 
Fig 2.6A: INS-1E cells). However, when CB5 is added along with PA, 50µM of CB5 
significantly reduces lipid accumulation in HepG2 cells (Figure 2.4C) and primary 
hepatocytes (Figure 2.5C). We also see a reduction in the lipid accumulation without 
palmitate addition and at 5 and 10µM CB5 conc., which could be the effect of CB5 in 
reducing the entry of fatty acids present in the media, and thus decreasing lipid 
accumulation. In INS-1E cells, 5µM CB5 significantly (p=0.001) reduced lipid 
accumulation at ≤250µM PA (Figure 2.6C). The effectiveness of CB5 in reducing lipid 
accumulation at much lower concentrations in INS-1E cells is advantageous since these 
cells do not generally store fat. This would help in further reducing or preventing the state 
of lipotoxicity and thus associated cellular dysfunction in diseased states of obesity, 
T2DM and hyperlipidemia [60].  
 
 High concentrations of saturated fatty acid, particularly palmitic acid also affect the 
nuclear integrity of the cells and thus leads to apoptosis [61]. This was assessed by  
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Figure 2.4: Effect of palmitate treatment on A) Lipid accumulation and B) Apoptosis in 
HepG2 cells, and inhibition of lipid accumulation (C) and apoptosis (D) by CB5 in HepG2 
cells. HepG2 cells were treated with different concentrations of palmitic acid (PA) (0-500μM) 
without or with CB5 (0-50μM) for 24hrs. Lipid accumulation was evaluated using the standard 
Nile Red assay and apoptosis using DAPI staining at excitation/emission of 485/590nm and 
360/460nm, respectively on a BioTek Synergy plate-reader (details in methods section). The data 
is expressed as quantification of fluorescence for Nile red and DAPI in RFUs/103 cells for three 
experiments assayed in triplicate. The data was compared using ANOVA (JMP 11.0) for CB5 
versus PA followed by Student’s t-test. Levels not connected by the same letter are significantly 
different at p<0.05. 
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Figure 2.5: Effect of palmitate treatment on A) Lipid accumulation and B) Apoptosis in 
primary hepatocytes and inhibition of lipid accumulation (C) and apoptosis (D) by CB5 in 
primary hepatocytes isolated from 129S1/SvImJ mice. Hepatocytes were treated in the same 
way as HepG2 cells. The data is expressed as quantification of fluorescence of Nile Red and 
DAPI in RFUs/103 cells for three experiments assayed in triplicate. The data was compared using 
ANOVA (JMP 11.0) for CB5 versus PA followed by Student’s t-test. Levels not connected by the 
same letter are significantly different at p<0.05.  
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Figure 2.6: Effect of palmitate treatment on A) Lipid accumulation and B) apoptosis in INS-
1E cells and inhibition of lipid accumulation (C) and apoptosis (D) by CB5 in INS-1E cells. 
INS-1E cells were treated in the same way as HepG2 cells. The data is expressed as 
quantification of fluorescence of Nile Red and DAPI in RFUs/103 cells for three experiments 
assayed in triplicate. The data was compared using ANOVA (JMP 11.0) for CB5 versus PA 
followed by Student’s t-test. Levels not connected by the same letter are significantly different at 
p<0.05. 
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using DAPI staining of live cells treated with increasing concentrations of PA. Increasing 
concentrations of DAPI staining is indicative of apoptosis [62]. As the concentration of 
palmitate increases, nuclear integrity of the cells is compromised thus leading to an 
increase in DAPI staining (Figure 2.4B, HepG2 cells; Fig 2.5B, Primary hepatocytes and 
Fig 2.6B, INS-1E cells). Ten µM of CB5 was effective in maintaining the nuclear 
integrity and thus protection from apoptosis in HepG2 and INS-1E cells treated with 
500µM PA (HepG2, Figure 2.4D; and INS-1E cells, Figure 2.6D). A trend was evident at 
lower concentrations of CB5 (5- 10µM) in primary hepatocytes (Figure 2.5D) and 50µM 
of CB5 significantly reduced DAPI staining and thus, protected the nuclear integrity of 
cells. 
 
2.2.5 Mechanism of action of atypical antipsychotics differs from CB5 
CB5 and atypical antipsychotics, chlorpromazine and clozapine and related compounds, 
were identified as inhibitors of FA uptake in humanized yeast during the HTS of two 
different libraries [48, 56]. In those screens, 80µM of chlorpromazine and clozapine 
showed intermediate levels of inhibition activity in yeast cells. In Caco-2 cells, the 
percent inhibition by chlorpromazine was only 50% at concentrations of 100µM and 10% 
at 10µM [56]. In order to compare the inhibitory effects of atypical antipsychotics with 
CB5, a set of second generation antipsychotics (SGA) known to cause hyperlipidemia 
[63] in schizophrenic patients were subjected to live cell assay [55] in HepG2 cells. The 
set of compounds tested included the SGAs Clozapine, Olanzapine, Quetiapine and 
Risperidone; along with a first generation antipsychotic (FGA) Haloperidol and a 
pancreatic lipase inhibitor, Orlistat. Orlistat was used as a control because it blocks the 
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activity of pancreatic lipase in the gut and thus prevents the breakdown of triglycerides 
from the diet. Unhydrolyzed TAGs are not converted into absorbable FA and are excreted 
undigested. However, it is associated with various adverse effects such as diarrhea, 
hypertension, depression, diabetic ketoacidosis and oedema. These side effects makes it 
unsuitable for use as a drug [64].  
 
All of the tested antipsychotic drugs were ineffective in inhibiting C1-BODIPY-C12 
uptake in HepG2 cells (concentration ranging from 0-640µM) (data not shown). As 
expected, Orlistat also had no effect on C1-BODIPY-C12 uptake since it’s a pancreatic 
lipase inhibitor and does not affect fatty acid uptake directly. CB5, on the other hand, 
could inhibit the uptake of C1-BODIPY-C12 with an IC50 of 9.6µM (see Figure 2.2A 
above). We also determined the extent of lipid accumulation in the presence of varying 
concentrations of PA (500-100µM) and 50 or 100µM AAP drugs, orlistat or CB5. All the 
compounds exhibited only modest decreases in lipid accumulation at concentrations of 50 
and 100µM (Table 2.2). Cells were also not protected against nuclear fragmentation, 
except modest protection by clozapine and quetiapine as evidenced by DAPI staining. 
Orlistat, which inhibits FA absorption by inhibiting pancreatic lipase, did not show any 
effect either, as expected. CB5, on the other hand, was protective against palmitate 
induced lipid accumulation and apoptosis (Figure 2.4C and D). 
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Table 2.2: Evaluation of lipid accumulation and apoptosis by antipsychotic drugs and 
Orlistat in HepG2 cells.  
 In HepG2 cells 
Name of compound 
(Type of compound/ 
Chemical class [65]) 
Lipid Accumulation  DAPI staining  
Clozapine 
(Atypical/ 
Dibenzodiazepines) 
  
Quetiapine 
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Risperidone 
(Atypical/ 
Benzisoxazoles) 
  
Cl
N
N
H
N
N
H3C
OH
O
N
N
N
S
F
O
O
N
N
N
N
H3C
H3C
N
N
N
H
N
SH3C
0 
20 
40 
60 
80 
100 
120 
0 100 500 
R
FU
 
[Palmitate] µM 
A   B   C   
   A   B   C 
A   B   C 
0 
200 
400 
600 
800 
1000 
0 100 500 
R
FU
 
[Palmitate] µM  
A  A  A 
 
 A  B   B  
  A  A  A 
0 
20 
40 
60 
80 
100 
120 
0 100 500 
R
FU
 
[Palmitate] µM 
   A   B   C 
   A   B   C 
A   B   C 
0 
200 
400 
600 
800 
1000 
0 100 500 
R
FU
 
[Palmitate] µM  
A  A 
     B   B 
    A   A 
         B   B 
 
  A  A   A 
0 
20 
40 
60 
80 
100 
120 
0 100 500 
R
FU
 
[Palmitate] µM 
  A   A   B 
   A   B   C 
 A   A   B 
0 
20 
40 
60 
80 
100 
120 
0 100 500 
R
FU
 
[Palmitate] µM 
   A  B  C 
 A   B  C 
A   B   B 
0 
200 
400 
600 
800 
1000 
0 100 500 
R
FU
 
[Palmitate] µM  
    A  A  A 
  A  A  A 
   A  A  A 
0 
200 
400 
600 
800 
1000 
0 100 500 
R
FU
 
[Palmitate] µM  
     A  A  A  
    A  A  A 
   A  A  A  
	  	  
35	  
Haloperidol 
(Typical/ 
Butyrophenones) 
  
Orlistat 
(Pancreatic lipase 
inhibitor)   
 
***No compound (black bars); 50μM (gray bars); and 100μM (white bars) compound 
treatment. Refer to Figure 2.4 (C and D) for CB5 data. The data is expressed as 
quantification of fluorescence of Nile Red and DAPI in RFUs/103 cells for three 
experiments assayed in triplicate. The data was compared using ANOVA (JMP 11.0) for 
compounds versus PA followed by Student’s t-test. Levels not connected by the same 
letter are significantly different at p<0.05. 
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2.3. DISCUSSION 
In a previous study from our lab, CB5 was identified as an inhibitor of FATP2-mediated 
fatty acid uptake in a HTS screening in yeast expressing humanFATP2 and was 
subsequently characterized further in cell lines that are models for liver, enterocytes and 
adipocytes [48]. In the present study, we have further assessed the activity of CB5 in cell 
lines that are models for pancreas, muscle and human adipocytes. CB5 was effective in 
inhibiting the uptake of fatty acid analog in INS-1E and C2C12 cells but the uptake 
inhibition was least efficient in human adipocytes, the store-house of fat. This is 
advantageous to us since we expect to re-route the excessive fat to adipose tissue and 
thus, reduce the propensity to develop lipotoxic diseases. Importantly, we have 
demonstrated that CB5 was able to attenuate lipid accumulation and apoptosis in HepG2 
cells, INS-1E cells and primary hepatocytes in a dose dependent manner thus confirming 
its role as a protectant against lipotoxic diseases. 
 
CB5 inhibits the uptake of long chain fatty acids as determined using FA analog C1-
BODIPY-C12 [48]. Long chain and very-long chain fatty acids move across the cell 
membrane using proteins in a carrier-mediated manner. However, short and medium 
chain fatty acid move across the cell membrane via diffusion. CB5 was ineffective in 
inhibiting the uptake of the medium chain FA analog BODIPY FL-C5 suggesting its role 
as a long chain FA uptake inhibitor. Further, it was the effective in inhibiting the uptake 
of very-long chain FA analog BODIPY FL-C16 in low micro-molar ranges. Thus, CB5 is 
specifically an inhibitor for long and very long chain fatty acids. This is in accordance 
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with our earlier data that show FATP2 has a preference for the uptake of long chain fatty 
acid and activation of very long chain fatty acids [33, 66].  
 
On the basis of aforementioned properties of CB5, we predicted that CB5 could be useful 
in attenuating lipotoxicity caused by saturated fatty acids in the diet. Western diet is 
constituted mainly of saturated fatty acids which is correlated with various life style 
diseases including non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus 
(T2DM) and insulin resistance [59, 67]. Also, palmitic acid is known to induce lipid 
accumulation and apoptosis in hepatocytes as well as pancreatic β-cells [62, 68]. Thus, 
CB5 was used to assess its protective effects against the saturated fatty acid, palmitic 
acid. After 24hrs of treatment with palmitic acid and CB5, CB5 was able to attenuate the 
lipid accumulation and protect from apoptosis in primary hepatocytes as well as cell lines 
that are model for liver and pancreatic β-cells in a dose dependent manner.  
 
Other potential hits identified during HTS involved the structurally related phenothiazine 
group of compounds. Chlorpromazine and clozapine, the atypical antipsychotic drugs, 
were also identified as hits [56].  Typical (or first generation antipsychotics-FGA) and 
atypical (or second generation antipsychotics-SGA) antipsychotics are used for the 
treatment of various mental disorders ranging from psychosis, bipolar disorder, 
depression and schizophrenia. The ability of FGA to cause extrapyramidal effects (EPS) 
such as acute dyskinesia’s and dystonic reactions, tardive dyskinesia, Parkinsonism etc. 
[69] led to the discovery of SGA, which had a greater ability to treat mental disorders 
without EPS. Unfortunately, atypical antipsychotics are known to cause other metabolic 
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side effects including weight gain, dyslipidemia, insulin resistance, glucose intolerance, 
overt diabetes [70, 71] and in rare cases diabetic ketoacidosis, thus increasing the risk of 
cardiovascular disease events [71, 72].  
 
Since clozapine and chlorpromazine were identified as inhibitors of fatty acid uptake in 
the yeast based assay system [56], we tested and compared a set of antipsychotic drugs in 
HepG2 cells with CB5 to provide insight into the mechanism of dyslipidemia caused by 
them. All the antipsychotics tested were unable to inhibit the uptake of FA-analog C1-
BODIPY-C12 in HepG2 cells. Also, they were unable to prevent lipid accumulation in 
HepG2 cells that were treated with palmitic acid along with compounds (antipsychotics 
and Orlistat). Olanzapine and clozapine have the greatest propensity for inducing weight 
gain followed by risperidone and quetiapine and least for FGA haloperidol [73]. 
However, olanzapine exhibited modest reductions in accumulation of lipid in cells at high 
concentrations of 50 or 100µM. CB5 was still the best compound in protecting the cells 
against the lipid accumulation and apoptosis caused by saturated fatty acid, palmitate. 
Various studies have recently associated the alterations in lipid metabolism caused by 
AAP to transcriptional dysregulation caused by sterol regulatory element-binding protein, 
SREBP1 and 2 in liver [74]. Inability of the SREBPs to control AMPK signaling [74] and 
triglyceride metabolism [75] leads to an increase in lipid synthesis and thus dyslipidemia. 
This suggests that antipsychotics cause weight gain from mechanisms that do not involve 
inhibition of fatty acid uptake using FATPs. 
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In summary, these studies confirm the role of CB5 as a FATP2-mediated fatty acid 
uptake inhibitor. The exact mechanism by which CB5 inhibits fatty acid uptake is still not 
clearly understood. However, CB5 is effective in inhibiting specific class of fatty acid 
that are transported in a protein-mediated manner and does not affect fatty acids that are 
transported via diffusion. It is also effective in inhibiting the transport of fat into the cell 
lines that do not normally store excess fat and is least effective in inhibiting the transport 
in the adipose tissue that is considered the storehouse of fat. CB5 was also protective 
against the accumulation of lipids and apoptosis generated by saturated fatty acid, 
palmitic acid, in cell lines that are models for liver and pancreatic β-cells. However, 
inability of atypical antipsychotics to inhibit the uptake of FA-analog in HepG2 cells or 
to protect them against palmitate-induced lipid accumulation and nuclear fragmentation 
confirms that a different mechanism is causing weight gain and dyslipidemia in 
schizophrenic patients and it does not involve FATPs. Thus, CB5 blocks fatty acid 
transport without affecting other cellular functions and helps to partition toxic fatty acids 
away from cells thus attenuating weight gain and dyslipidemia in lipotoxicity related 
diseases. 
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2.4.MODEL DEPICTING CB5 ACTION IN-VITRO  
Small molecule inhibitors targeting fatty acid uptake in cells that might be subjected to 
lipotoxicity is proposed as a therapeutic approach in the treatment of disease states 
caused by excessive lipid accumulation. Ectopic lipid accumulation, a state of 
lipotoxicity, acts as a starting point for the progression of other diseased states including, 
but not limited to, glucose intolerance, insulin resistance, dyslipidemia, hypertension, 
cardiomyopathies etc. [51]. CB5 was identified as an inhibitor of FATP2-mediated fatty 
acid uptake in yeast transformed with humanFATP2. Further in-vitro studies validated 
the ability of CB5 in inhibiting fatty acid uptake in mammalian cell lines without being 
toxic and affecting other activities in the cell such as glucose transport. In this study, we 
further characterize CB5 for its ability to inhibit fatty acid uptake in other cell lines that 
work in the complex metabolic system involved in lipid metabolism. CB5 was effective 
in inhibiting fatty acid uptake in FATP2 expressing cell lines including HepG2, Caco-2, 
INS-1E and C2C12 cell. Adipocytes that do not express FATP2, but FATP1, were not 
affected by the presence of CB5 in culture and took up fatty acids normally (Figure 2.7). 
Further, the specificity of CB5 in inhibiting very long chain fatty acid is demonstrated 
using FA-analog BODIPY FL C16. The uptake of medium chain fatty acid analog 
BODIPY FL C5 is not affected by CB5, as expected, since medium chain fatty acids 
enter cells via diffusion. Finally the ability of CB5 to attenuate lipid accumulation and 
protect liver and pancreatic cells from nuclear damage caused by saturated fatty acid, 
palmitic acid adds to its therapeutic potential.  
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Figure 2.7: A model depicting the potential of CB5 as a FATP2-mediated fatty acid uptake 
inhibitor in cell lines that are model for liver, enterocytes, pancreatic cells and muscles. 
Inhibition was not effective in adipose tissue, the storehouse of fat. Also, CB5 is efficient in 
attenuating lipotoxicity generated by saturated fatty acid, palmitic acid in liver and pancreatic 
cells. 
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Chapter 3 
 
 
 
 
 
PHARMACOKINETIC ANALYSIS OF FATTY ACID TRANSPORT PROTEIN 2-
MEDIATED FATTY ACID UPTAKE INHIBITORS, CB5 AND CB16.2. 
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ABSTRACT 
 
Pharmacokinetic properties of a drug describe the fate of the compound when delivered 
exogenously to an organism and include the intensity and the time course of the 
therapeutic dosage and determination of the toxic effects of the drugs. The properties of 
drug absorption, distribution, metabolism and excretion (ADME) constitute an integral 
part of the pre-clinical studies before a drug can be marketed. Thus all these properties 
help estimate the therapeutic potential of the compound/drug being tested. Here we 
determine pharmacokinetic parameters of compounds identified as inhibitors of fatty acid 
uptake in-vitro and in-vivo. CB16.2 (5’-bromo-5-phenyl- spiro[3H-1,3,4-thiadiazole-2,3’-
indoline]-2’-one) was more soluble and stable as compared to CB5 in different solvents 
tested over range of temperatures. The half-life of CB5 and CB16.2 via intravenous 
injections was 151.7 and 97.8 minutes respectively. We also employed oleate uniformly 
labeled with 13C to evaluate FA uptake inhibition by CB5 and CB16.2 in-vivo. A single 
oral dose of 300mg/kg was effective in reducing the uptake of 13Coleate by 50% in 2hrs by 
CB16.2 and 37% in 6hrs by CB5 post-administration. Both the compounds were readily 
detected in the plasma samples in a time dependent manner after gavage using LC/MS 
analysis. This confirms the potential role of CB5 and CB16.2 as therapeutics against 
diseases caused by high levels of saturated fat in the diet. 
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3.1.INTRODUCTION 
Pharmacokinetic (PK) properties of a drug are the primary determinant of extent of drug 
duration and action and other interactions that are clinically important for improvements 
in drug discovery. Pharmacokinetics is the quantitative study of drug absorption, 
distribution, metabolism and excretion (ADME properties) (Figure 3A). Absorption or 
oral bioavailability of a drug is defined as the amount of drug in the systemic circulation 
after passing through intestinal epithelium. Once in circulation, the volume of 
distribution, i.e. the fraction of drug bound in plasma, as well as its distribution to various 
organs and tissues is evaluated. Finally, the metabolism of drug in liver or kidneys and its 
excretion is studied to understand its activity in an organism. These ADME properties 
also help to determine the time course of therapeutic and toxicological effects of the drug 
and thus, increase its efficacy [76, 77]. Most of the drugs never go beyond the clinical 
trial stage because of their poor pharmacokinetic properties.  
 
 
	  
Figure 3A: Absorption, distribution, biotransformation (metabolism), and excretion of a 
typical drug after its oral administration [78]. 
 
 
11C H A P T E R  2  ■ Pharmacokinetics
(pK a = 8 – 10) will predominate. Hence, weak acids are more 
readily absorbed from the stomach than are weak bases. In 
the intestines, with a pH of 7, weak bases are also mostly ion-
ized, but much less so than in the stomach, and weak bases 
are absorbed more readily from the intestines than from the 
stomach. 
 However, weak acids can also be absorbed more readily 
from the intestines than from the stomach, despite their 
greater ionization in the intestines, because the intestines 
have a greater surface area than the stomach for absorption 
of the non-ionized form of a drug, and this outweighs the 
influence of greater ionization in the intestines. 
 DRUG DISTRIBUTION 
 Drugs are distributed to organs and tissues via the circula-
tion, diffusing into interstitial fluid and cells from the circu-
lation. Most drugs are not uniformly distributed throughout 
total body water, and some drugs are restricted to the 
extracellular fluid or plasma compartment. Drugs with suf-
ficient lipid solubility can simply diffuse through mem-
branes into cells. Other drugs are concentrated in cells by 
the phenomenon of  ion trapping , which is described further 
below. Drugs can also be actively transported into cells. For 
example, some drugs are actively transported into hepatic 
cells, where they may undergo enzymatic biotransformation. 
In the intestines, drug transport by  P-glycoprotein (Pgp) in 
the blood-to-lumen direction leads to a secretion of various 
drugs into the intestinal tract, thereby serving as a detoxify-
ing mechanism. The Pgp proteins also remove many drugs 
from tissues throughout the body, including anticancer 
agents. Inhibition of Pgp by amiodarone, erythromycin, 
propranolol, and other agents can increase tissue levels of 
these drugs and augment their pharmacologic effects. 
 Factors Affecting Distribution 
 Organ Blood Flow 
 The rate at which a drug is distributed to various organs 
after a drug dose is administered depends largely on the 
proportion of  cardiac output received by the organs. Drugs 
are rapidly distributed to highly perfused tissues, namely the 
brain, heart, liver, and kidney, and this enables a rapid onset 
of action of drugs affecting these tissues. Drugs are distrib-
uted more slowly to less perfused tissues such as skeletal 
muscle and even more slowly to those with the lowest blood 
flow, such as skin, bone, and adipose tissue. 
 Plasma Protein Binding 
 Almost all drugs are reversibly bound to plasma proteins, 
primarily  albumin , but also lipoproteins, glycoproteins, and 
 β globulins. The extent of binding depends on the affinity of 
a particular drug for protein-binding sites and ranges from 
less than 10% to as high as 99% of the plasma concentration. 
As the free (unbound) drug diffuses into interstitial fluid 
and cells, drug molecules dissociate from plasma proteins 
to maintain the equilibrium between free drug and bound 
drug. In general, acid drugs bind to albumin and basic drugs 
to glycoproteins and  β globulins. 
 Plasma protein binding is  saturable , and a drug can be 
displaced from binding sites by other drugs that have a high 
affinity for such sites. However, most drugs are not used at 
high enough plasma concentrations to occupy the vast num-
ber of plasma protein binding sites. There are a few agents 
that may cause drug interactions by competing for plasma 
protein binding sites, as highlighted in  Chapter 4. 
 Molecular Size 
 Molecular size is a factor affecting the distribution of extremely 
large molecules, such as those of the anticoagulant  heparin . 
Heparin is largely confined to the plasma compartment, al-
though it does undergo some biotransformation in the liver. 
 Lipid Solubility 
 Lipid solubility is a major factor affecting the extent of drug 
distribution, particularly to the brain, where the  blood-
brain barrier restricts the penetration of polar and ionized 
molecules. The barrier is formed by tight junctions between 
the capillary endothelial cells and also by the glial cells that 
surround the capillaries, which inhibit the penetration of 
polar molecules into brain neurons. 
 DRUG BIOTRANSFORMATION 
 Drug  biotransformation and  excretion are the two pro-
cesses responsible for the decline of the plasma drug concen-
tration over time. Both of these processes contribute to the 
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 F igure  2  –  1 .   The absorption, distribu-
tion, biotransformation (metabolism), and 
excretion of a typical drug after its oral ad-
ministration. 
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Obesity and the related disease states such as dyslipidemia, hypertension, diabetes 
mellitus and ultimately heart disease have increased many fold in the past 20 years. 
Lifestyle modifications and pharmacological interventions are being considered in an 
effort to reduce the progression of metabolic syndrome and cardiovascular diseases. 
Metabolic syndrome (MS) is characterized by cluster of metabolic disorders including 
abdominal obesity, dyslipidemia, hypertension and impaired fasting glucose. Drugs either 
in use or in development are directed towards one or more aspects of the metabolic 
syndrome, however none are capable of significantly reducing cardiovascular events in 
the patients [46]. This is due to side effects caused by these drugs in long run, thus 
questioning the clinical utility of the compounds. Thus pharmaceutical interventions that 
narrowly target the involved metabolic pathway without deleterious side effects are the 
target of the drug discovery process [79, 80].  
 
Targeting the protein-mediated mechanism of fatty acid uptake and inhibiting the uptake 
of fatty acid are proposed as potential therapeutics towards preventing and curing these 
diseases. Inhibitors targeting the family of fatty acid transport proteins (FATPs) are under 
study. FATP1 [52, 53], FATP2 [48] and FATP4 [54] inhibitors are available. FATP1 and 
FATP4 inhibitors are targeted against the acyl-CoA synthetase activity of the FATPs 
rather than the transport activity. A previous and current study from our lab describes 
FATP2 inhibitors specific to the transport activity of fatty acids [48, 55]. Both CB5 and 
CB16.2 inhibitors were identified during a high throughput screening assay in humanized 
yeast and are efficient in inhibiting the uptake of FA in various cell lines that are models 
for liver, intestines, muscle, pancreas and adipose tissue.  
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In the present study, we have determined the solubility, tolerability, stability and 
pharmacokinetic properties of CB5 and CB16.2 via various routes of administration to 
establish their suitability as a potential therapeutic drug.  
3.2.RESULTS  
The solubility, stability and pharmacokinetic data were obtained under a service contract 
from University of Kansas Biotechnology Innovation and Optimization Center, 
Lawrence, KA. 
 
3.2.1. Solubility and stability 
Solubility studies were carried out to determine different solvents suitable for complete 
dissolution of CB5 and CB16.2. The extinction coefficient for a particular compound is 
constant under defined conditions and can be used to determine the concentration of 
various other formulations. The extinction coefficient for CB16.2, determined at a 
wavelength of 305nm, was 7,363 cm L/Mole in methanol. CB16.2 was insoluble in 
stimulated gastric fluid (SGF) and pH 7 phosphate buffered saline (PBS). It was 
effectively soluble in 75% iso-propyl alcohol (IPA)-25% water. By contrast, 4.8mg/ml 
and 6.5mg/ml of CB16.2 was soluble in methanol and ethanol respectively. The solubility 
of CB16.2 was highest in solutol-HS (28mg/ml). The limit of quantitation (LOQ) as 
determined using LCMS studies was 2.6µg/ml (7.3µM) for CB16.2. 
 
The extinction coefficient of CB5 determined at a wavelength of 272nm was 27,500 cm 
L/Mole in methanol. CB5 was also not soluble in stimulated gastric fluid (SGF) and pH 7 
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phosphate buffered saline (PBS). Four mg/ml of CB5 was soluble in solutol HS-15 
whereas only 0.7mg/ml was soluble in polysorbate 80 (Tween 80) at 20% solution in 
water. Various other solvents such as Vitamin E TGPS, labrasol, captisol and Poloxamer 
188 (Pluronic F-68) were tested for the solubility studies of CB5 but none was effective 
in solubilizing more than 1mg/ml of CB5 and it precipitated out within 24hrs. The limit 
of quantitation (LOQ) as determined using LCMS studies was 1.9µg/ml (4.2µM) for 
CB5.  
 
A stability study of CB16.2 was performed at 5°C, 25°C, 40°C and 60°C for 14 days. 
Based on UV data, CB16.2 was stable at 5°C and 25°C, but some degradation was 
observed at 40°C and more at 60°C sample for a period of 14 days and up to 24 days. 
CB5 was stable for 2 days at room temperature.  
 
Thus CB16.2 was soluble in hydrophilic solutions and insoluble in water and was stable 
for longer periods of time. On the other hand, CB5 was less soluble than CB16.2 in 
hydrophilic solutions and was stable for up to 24hrs. Considering the solubility and 
stability data, Solutol-HS was determined the solvent of choice and used for drug 
administration studies.  
 
3.2.2. Pharmacokinetic parameters of CB5 and CB16.2 
3.2.2.1. Tolerability 
CB5 and CB16.2 were solubilized in solutol-HS 15 for the PK studies. The maximum 
tolerated dose for CB5 via intravenous (IV) injection was 4mg/kg and 2mg/kg was used 
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for PK studies. For CB16.2, the first dose of 4mg/kg via IV injection made the mouse 
motionless for about 20 minutes with normal breathing. Mouse legs were extended when 
picked up as though it was protecting itself from a fall suggesting that equilibrium might 
have been impacted. However, the mice regained consciousness after 20mins and were 
essentially back to normal after 1 hour and 40 minutes. The maximum tolerated dose via 
IV was 4mg/kg and therefore 2mg/kg was used for PK studies. While at this dose the 
mice also lost consciousness for 5 minutes, but then fully recovered after 12 minutes. For 
subcutaneous (SQ) and intra-peritoneal (IP) dosing of CB16.2, some adverse effects were 
seen at 8mg/kg dose, so the PK studies were carried out at 4mg/kg dosage. Both the 
compounds were well tolerated without neurological abnormalities at a dose of 300mg/kg 
when administered orally (via gavage). 
 
3.2.2.2. Absorption, distribution and excretion 
PK parameters were determined for CB5 and CB16.2 via IV, IP and SQ after solubilizing 
in solutol-HS (Figure 3.1 and Table 3.1). The area under the plasma drug concentration-
time curve (AUC) is used to determine the amount of time the body is exposed to drug 
after different routes of administration. The AUC (from zero to time infinity) for CB5 
and CB16.2 after different routes of administration are shown in Table 3.1. When CB5 
was administered via IV, the half-life was determined to be 151.7 min. The AUC for 
plasma concentration versus time for CB5 was 1191030 min*ng/ml and the time required 
for CB5 to reach its maximum concentration in the plasma (Cmax) were 30mins (Tmax). 
The volume of distribution (Vd) for CB5 in circulation was 502.9ml/kg and clearance was 
1.9 ml/min/kg.  
	  	  
49	  
 
For CB16.2, the half-life in blood was 97.8, 38.6 and 12 minute after administration via 
IV, IP and SQ administration, respectively. The AUC varied significantly between 
different routes of administration of CB16.2 thus predicting the availability of drug in the 
circulation. The absorption of drug is considered 100% after IV administration [77]. The 
AUC for CB16.2 via IV administration was highest and it was metabolized quickly over 
short period of time (Figure 3.1). When administered via SQ, CB16.2 showed higher 
AUC that gradually decreases with time. This suggests that it stays longer in the 
circulation when administered subcutaneously but the amount decreases eventually as 
evident in Figure 3.1. When administered via IP injection, the AUC for CB16.2 was 
highest but for shorter periods of time. Thus, CB16.2 was rapidly absorbed and excreted 
after IV administration. It was also rapidly excreted after IP administration, however, the 
absorption and excretion was reduced after SQ administration.  
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Figure 3.1: Area under plasma drug concentration-time curve (AUC) for CB5 and CB16.2 
after different routes of administration in mice as obtained under a service contract from 
University of Kansas Biotechnology Innovation and Optimization Center, Lawrence, KA. Mice 
were dosed with specified concentrations of CB5 and/or CB16.2 (dissolved in solutol) and blood 
was collected at 0, 15, 30, 60, 120, 240, 480 and 720 minutes for n=3 mice at each time point. 
Plasma samples were subjected to LC/MS/MS analysis for detection of CB5 and CB16.2 using a 
method optimized at the University of Kansas. I.V., intravenous injection; I.P., intraperitoneal 
injection; and S.Q., subcutaneous injection. 
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Table 3.1: Pharmacokinetic parameters of CB5 and CB16.2 obtained after different routes 
of compound administration 
PK 
Parameters 
CB5 - IV (2mg/kg) 
CB16.2 - IV 
(2mg/kg) 
CB16.2 – SQ 
(4mg/kg) 
CB16.2 – IP 
(4mg/kg) 
Slope (1/min) 0.0080±0.007 0.0071 0.0242±0.01 0.0744±0.05 
Half-life (min) 151.7±108.4 97.8 38.6±28.7 12.0±6.3 
Tmax (min) 30.0±26 5.0 30.0±0 15.0±0 
Cmax (ng/ml) 22773.3±27045.4 607.3 140.7±30.7 908.7±730.7 
AUC0-∞ 
(min*ng/ml) 
1191030.3±556125.2 18589.8 9971.9±6685.7 18510.5±9581.7 
Vd (ml/kg) 502.9±470.5 15176.8 22173.2±4445.9 4924.8±3563.8 
CL 
(ml/min/kg) 
1.9±0.8 107.6 528.7±300.3 250.6±100.1 
**Tmax: time at which drug levels are at peak in blood; Cmax: maximal plasma levels or 
concentration of drug; AUC0-∞: area under plasma drug concentration-time curve from 
0min to ∞; Vd: volume of distribution of drug in plasma; and CL: clearance, rate of 
elimination of drug by metabolism and excretion. 
**IV: Intravenous; SQ: Subcutaneous; IP: Intra-peritoneal 
**Data is represented as mean ± SD for n=3; mean and SD could not be determined for 
some subjects administered CB16.2 via IV dose since many of the samples were below 
the quantitation limit (BQL) which is less than 25ng/ml of CB16.2 by LC/MS/MS. 
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After IV administration of CB16.2, the peak levels of CB16.2 (Cmax: 607.3 ng/ml) in the 
circulation are achieved in 5 min (Tmax). The Vd is also higher suggesting large amount of 
free drug is available in the circulation for short periods of time and is cleared quickly. 
Similarly, after IP injection of CB16.2, though it takes longer time to reach its maximal 
levels (Cmax, 908.7 and Tmax, 15 min) and is absorbed slowly than IV administration, it is 
excreted quickly. Finally, SQ administration of CB16.2 causes it to leach slowly in the 
circulation and stays for longer periods of time causing delay in reaching maximum 
levels in blood (Tmax, 30 min) and is cleared slowly compared to other routes of 
administration.  	  
3.2.2.3. Metabolism 
Drug metabolism or biotransformation refers to the conversion of a drug to its 
metabolites [78]. It usually occurs in the liver but can occur in gastrointestinal tract, 
lungs, kidney, skin or plasma. Metabolism studies are important to determine the 
modifications that may occur in a drug due at least in part to cytochrome P450 enzymatic 
modification in the liver. These transformations can render drug more active, inactive or 
toxic than the parent drug [81]. The most common in-vitro method used for metabolism 
studies are liver microsomes though isolated hepatocytes, recombinant CYP isozymes, 
liver slices and in-situ gastrointestinal/liver single pass perfusion preparations could also 
be used [82]. The metabolism of CB5, in-vitro, was determined using mouse (Table 
3.2A) and human (Table 3.2B) microsomes. As shown in Table 3.2, CB5 was 
metabolized quickly by the mouse microsomes as compared to human microsomes. After 
15mins of incubation with 2µM CB5, 56.54% of CB5 was converted into a new product 
by mouse microsomes as compared to just 26.32% by human microsomes. After 1hr, 
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almost 87% of the CB5 was converted/metabolized by mouse microsomes, whereas, only 
66.7% was metabolized by human microsomes. On the other hand, 98% of CB16.2 was 
converted into a new product over 1hr assay period by mouse microsomes whereas 
human microsomes converted only 55% of the compound to a new product (data not 
shown). Further studies are needed to identify the secondary metabolites that are formed 
or transformations that may occur in CB5 and CB16.2 after liver metabolism. 
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Table 3.2: In-vitro metabolism of CB5 using A) mouse; and B) human liver microsomes. 
Species (Mouse, Balb-C) 
Time  [CB5] Mean Standard 
Deviation 
% 
Converted 
(min) (ng/mL) (ng/mL)     
0 5000 4750.67 391.03 0 
0 4952       
0 4300       
15 2001 2064.67 130.70 56.54 
15 2215       
15 1978       
30 669 724.67 67.68 84.75 
30 705       
30 800       
60 600 615.33 27.43 87.05 
60 647       
60 599       
 
Species (Human, pooled) 
Time  [CB5] Mean Standard 
Deviation 
% 
Converted 
(min) (ng/mL) (ng/mL)     
0 6600 6217 1029.40 0 
0 7000       
0 5051       
15 4400 4580.66 275.69 26.32 
15 4444       
15 4898       
30 2500 2436.33 118.15 60.81 
30 2509       
30 2300       
60 2000 2067.33 58.38 66.74 
60 2104       
60 2098       
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3.2.3. Development of method for detection of 13C label in plasma samples 
Stable isotope-labeled compounds combined with mass spectrometry are used 
extensively in biomedical research to study various aspects of metabolism and 
pharmacokinetics of drugs and other compounds in animal models and humans. 
Deuterium and carbon-13 are the most commonly used stable isotopes [83]. In the present 
study, we have utilized stable isotope caron-13 labeled oleic acid and developed a method 
to detect the label in plasma samples using gas chromatography-mass spectrometry. 
Hundred micrograms of 13C18-oleate and 12C-oleate (unlabeled oleate) were weighed out 
and subjected to methyl ester formation using sulfuric acid in methanol and toluene [84]. 
Following derivatization, the methyl esters were extracted in hexanes and an aliquot was 
removed for GC/MS analysis. Samples were analyzed using an Agilent 7890A gas 
chromatography unit linked to an Agilent 5975C VL MSD (mass selective detector) 
(Agilent, Palo Alto, CA) using electron impact ionization. GC was performed using an 
Agilent CP7421 Select FAME column, 200 m X 275 µm X 0.25 µm. The oven 
temperature was set as a gradient of 10°C /min from 130°C for 10 min, then to 160°C for 
2 min; then to 190°C for 5 min; then to 220°C for 10 min and finally to 250°C for 10 
min. The total run time was 49 minute. Samples (1µl) were injected in a splitless mode. 
The mass spectrometer settings were set to selective ion monitoring (SIM) mode. The 
mass selective detector was set for selective ion monitoring of m/z 264 and 296 for the 
methyl ester of endogenous 12C oleate and m/z 282 and 314 for the methyl ester of 13C18 
oleate, using 100ms dwell time per ion. The m/z of 282 and 314 for 13C18 oleate 
represents 18+ carbons added to the endogenous 12C oleate, thus increasing the mass 
from 264 to 282 and from 296 to 314. 
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As shown, a single peak representing the total ion chromatogram (TIC) of 12C- oleate was 
detected at a retention time (RT) of 43.395 minute (Figure 3.2A) and RT of 13C18- oleate 
at 43.374 minute (Figure 3.3A). A slight delay in retention time of labeled oleate is 
expected to be due to the addition of 18 carbons. The fragmentation pattern of unlabeled 
and labeled oleate as it passes through the mass spec is shown in Figure 3.2B and 3.3B, 
respectively. To determine the abundance of the ions fragments specific to unlabeled and 
labeled oleate, ions with m/z 264, 296, 282 and 314 were extracted for both 12C-oleate 
and 13C18 oleate as shown in Figure 3.2C and Figure 3.3C, respectively. As expected, the 
12C-oleate did not show any peaks for m/z 282 and 314 due to the absence of label. On 
the other hand, the sample of 13C18 oleate exhibited m/z of 264 and 296 corresponding to 
unlabeled oleate along with ion fragments for labeled oleate (m/z 282 and 314). The 
detection of ion fragments corresponding to unlabeled oleate in 13C18 oleate sample could 
be due to the presence of endogenous oleate in the sample or background from the 
instrument. Due to inconsistency of data obtained from ion fragments with m/z 264 and 
282, they were not used for data analysis in the further experiments. 
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Figure 3.2: A) Total Ion chromatogram (TIC) of 12C- oleate, B) ion fragmentation pattern of 
12C-oleate peak highlighting m/z 296; and C) Ion chromatograms for ion fragments specific 
to 12C- and 13C18- oleate.  
	  
Figure 3.3: A) Total Ion chromatogram (TIC) of 13C18 oleate, B) ion fragmentation pattern 
of 13C18 oleate peak highlighting m/z 314; and C) Ion chromatograms for ion fragments 
specific to 12C- and 13C18- oleate.  
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3.2.4. Prevention of fat absorption in-vivo 
In order to evaluate the inhibition of FA absorption by CB5 in a live animal, we orally 
administered CB5 or CB16.2 to mice one hour prior to oleate labeled uniformly with 13C 
stable isotope and then blood was collected at different time points. As shown in Figure 
3.4A, a single gavage of CB5 (300mg/kg concentration) was effective in reducing the 
levels of labeled oleate by 37% 6hrs post-label administration. The levels of CB5 in 
plasma varied from 2.1±0.6 ng/µl at 0.5hrs to 3.4±0.7 ng/µl at 2hrs and then were reduced 
to 2.9±0.7 ng/µl at 6hrs (Figure 3.4B).  
 
CB16.2, on the other hand, was effective in reducing the uptake of labeled oleate and 
exhibited a significant reduction in the levels at 2hr and 6hr (p≤0.001) (Figure 3.4C). It 
was effective in reducing the uptake of 13Coleate by almost 50% at 2hr and 75% at 6hr 
compared to controls. The levels of CB16.2 in the plasma samples were also detected 
using LC/MS. As shown in Figure 3.4D, there was a slight increase in the levels of 
CB16.2 from 1.7ng/µl at 0.5hr to 1.8ng/µl at 2hr, followed by a reduction to 1.3ng/µl in 
plasma at 6hr.  
 
Thus, this confirms the inhibitory action of CB5 and CB16.2 in vivo and their 
effectiveness in preventing the uptake of fatty acids across the intestinal epithelium. 
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Figure 3.4: Inhibition of fatty acid uptake and absorption by A) CB5 and C) CB16.2 in 12-
weeks old C57Bl/6 mice. Mice were gavaged with 300mg/kg of CB5, CB16.2 or control for 1hr 
followed by 500mg/kg of 13C-oleate and blood collected via cardiac puncture at 0.5, 2 and 6hrs. 
The plasma were subjected to lipid extraction and the presence of label detected using selective 
ion monitoring of 314 and 296 peaks for labeled and unlabeled ions indicative of C18:1 
respectively. The data is represented as the average of 314 to 296 ions in plasma samples (A and 
C). The levels of (B) CB5 and (D) CB16.2 in plasma samples at different time points were 
detected using LC/MS/MS analysis as detailed in the legend of Figure 3.1 and a representative 
chromatogram is shown in Figure 3.3. Bar height indicates the mean of 8-12 mice ±SE. The data 
was compared using ANOVA (JMP 11.0) for CB5 versus control at different time points 
followed by a post-hoc test using Student’s t-test.  
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3.3.DISCUSSION 
Evaluation of the pharmacokinetics of a drug is important to determine it as a potential 
therapeutic for further clinical trials. Here we describe the pharmacokinetic properties of 
two small molecule inhibitors, CB5 and CB16.2, which were identified as FATP2-
mediated fatty acid uptake inhibitors during a high throughput screening. Both the 
inhibitors were soluble in wide range of solvents although CB5 was not soluble beyond 
1mg/kg and precipitated out easily in most of the solvents tested. The best solvent for 
both was solutol. They were also tested for their pharmacokinetic properties via different 
routes of administration. Both of them were also well tolerated at doses of 2mg/kg via IV 
and CB16.2 was well-tolerated up to 4mg/kg via SQ and IP. The oral administration was 
also not toxic at dosage as high as 300mg/kg.  
 
As soon as the drug is administered, it reaches the blood stream, a process known as 
absorption. Absorption is not considered for IV administration because of its quick 
distribution. For all other routes, absorption is an important parameter. In the circulation, 
the drug is distributed between plasma and blood cells and also between plasma proteins. 
Most drugs reach the extracellular fluid of various organs by crossing the capillaries 
whereas lipid soluble drugs cross the cell membrane and reach the extracellular fluid of 
every organ. This is known as distribution (movement of drug from blood to various 
organs). Finally, a drug is eliminated through the body of an organism either indirectly by 
enzymatic or biochemical transformation in liver (a process called metabolism) or 
directly excreted via urine, bile etc. (a process called elimination). Thus, PK is the 
quantitative study of time course of all these parameters [77, 81].  
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The area under curve (AUC) is an analytical method used to determine other PK 
parameters of a drug. AUC is basically a measure of the drug concentration vs. time and 
is calculated by considering the curve as several trapezoids and estimating the total area 
of all those trapezoids [77]. AUC is also dependent on the rate of elimination of the drug 
from the body and the dose administered. The AUC is directly proportional to the dose 
when the drug appearance or disappearance follows linear kinetics. It is important to 
determine AUC since it is inversely proportional to the clearance of the drug. That is, the 
higher the clearance, the less time the drug spends in the systemic circulation and the 
faster the decline in the plasma drug concentration. Therefore, in such situations, the 
body exposure to the drug and the area under the concentration-time curve are smaller 
[82, 85]. AUC for CB5 via IV administration is high which means more amount of CB5 
is available in circulation but for shorter period of time. However, whether the drug is 
available for its action or not is determined by volume of distribution.  
 
The volume of distribution (Vd) determines the bioavailable dose or concentration of the 
drug in the plasma [78]. There is an uneven distribution of drug throughout the body and 
some areas such as central nervous system or brain are weakly accessible to certain drug 
as compared to others. At equilibrium, the drug concentration in plasma is considered 
proportional to the amount of drug administered intravenously. Vd is affected by the 
binding of drug to plasma proteins such as albumin and α-glycoprotein in the circulation. 
When drugs are bound to plasma proteins, Vd decreases, thus, decreasing the unbound 
drug in plasma for therapeutic effects [77]. This was evident for CB5 as its Vd was low, 
which means CB5 was bound to plasma proteins such as albumin in blood and a very 
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small amount was available as a free drug to be taken up by tissues. On the other hand, 
Vd for CB16.2 was higher suggesting it is not bound to plasma proteins and free CB16.2 
is available to be taken up tissues when administered intravenously.  
 
Clearance of a drug is one of the most important PK parameters. It is dependent on the 
ability of liver and kidneys to metabolize or excrete drug from the body. It is defined as 
the volume of blood cleared through an organ in a unit of time. The clearance of a drug 
cannot be determined after oral administration, as total drug dose does not reach the 
circulation [77, 85]. Clearance of CB5 after IV administration was very low suggesting 
very small volume of blood is cleared through an organ. This is in accordance with Vd 
data, which suggests large concentration of CB5 is bound to plasma proteins and is not 
available for organ uptake. The clearance of CB16.2 was higher when administered 
intravenously and correlated with volume of distribution. 
 
To understand the role of CB5 and CB16.2 in the absorption of fatty acids across gut, a 
pilot study in mice was conducted. The complexity and involvement of different organs 
in fatty acid metabolism could only be understood in a whole animal. In-vivo study 
involving mice exhibited the efficacy of both the compounds in inhibiting the uptake of 
fatty acids across the intestinal epithelium. Detection of both the compounds in the 
plasma as soon as 30mins after gavage further adds to its effectiveness. CB5 effectively 
reduced uptake of labeled oleate after 6hrs of gavage and CB16.2 inhibited the uptake 
after 2hrs. The trafficking of the label to different tissues could not be determined due to 
the co-treatment with tyloxapol, a plasma lipase inhibitor. Other inhibitors belonging to 
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the family of fatty acid transport proteins were specific for the acyl-CoA synthetase 
activity of FATP1 and FATP4. Only in-vitro data exhibited efficacy of these inhibitors in 
reducing lipid accumulation. However FATP1 and/or FATP4 inhibitors, when 
administered orally to high fat diet fed mice, were ineffective in reducing triglyceride 
accumulation in skeletal muscle, liver and small intestines, tissues that express FATP1 
and FATP4 respectively [52, 54]. We conclude this was due to inability of inhibitors to 
inhibit FA uptake as well as activation. Since no other known drug inhibits the fatty acid 
uptake in this manner, CB5 and CB16.2 could be used as a potential therapeutic. 
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3.4.MODEL DEPICTING CB5 ACTION IN-VIVO 
The potential of CB5 as a small molecule inhibitor of FATP2-mediated fatty acid uptake 
is described in chapter 2. However, in-vitro studies are unable to imitate the complex 
system in-vivo that involves interaction of various tissues and organs. Pharmacokinetics 
studies of a drug are important to determine its efficacy and potency of a drug in a whole 
organism before it can be moved further for clinical trials. In this study, we have 
determined the ADME properties of CB5 and CB16.2, small molecule inhibitors of 
FATP2-mediated FA uptake, to establish their potential as a pre-therapeutic. Both the 
inhibitors were tested for their solubility and stability in various solvents but the best 
solvent was solutol-HS, which was used for determining pharmacokinetic parameters. 
CB5 was less soluble and had a longer half-life when administered via IV. CB16.2 was 
easily soluble and stable in different solvents tested. They were well tolerated at doses of 
up to 300mg/kg via oral administration. In mice models, both the inhibitors were 
administered orally to determine their efficacy in attenuating the absorption of labeled 
oleate via intestinal epithelium. The epithelial cells of the small intestine express FATP2 
and reduction in absorption of labeled oleate would serve to demonstrate the specificity 
of FATP2-mediated fatty acid uptake inhibition by inhibitors across gut. Figure 3.5 
presents a model depicting the activity of CB5 in reducing adsorption of labeled oleate 
across gut as compared to control that does not inhibit absorption. CB5 was also 
detectable in the circulation as soon as 30 min after label administration. The mechanism 
by which CB5 inhibits absorption of fatty acid across gut needs to be elucidated. (Model 
for CB16.2 not shown but works in the same way as demonstrated for CB5). 
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Figure 3.5: Movement of labeled oleate across intestinal epithelium after oral 
administration of control, flaxseed oil (top panel), or CB5 (bottom panel). Under normal 
conditions, the absorption of labeled oleate occurs across the intestinal epithelium and the 
chylomicrons containing labeled oleate are exocytosed in the lymphatic vessel. However, when 
CB5 is administered one hour prior to labeled oleate, a reduction in absorption of labeled oleate 
across the gut is evident followed by reduction of label in the plasma samples as detected by 
GC/MS. CB5 is detected in the circulation as soon as 0.5hr after label administration. 
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Chapter 4 
 
 
 
 
 
WHOLE BODY KNOCKOUT OF THE FATTY ACID TRANSPORT PROTEIN-2 
(FATP2) GENE IN 129S6/SVEV MICE SIGNIFICANTLY IMPROVES PLASMA 
TRIGLYCERIDE LEVELS BUT DEVELOP STEATOTIC LIVERS. 
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ABSTRACT 
Obesity, hyperlipidemia, atherosclerosis and type 2 diabetes are all considered lifestyle-
related diseases caused by excessive food intake and a sedentary lifestyle. Cardiovascular 
morbidity is further increased by clustering of metabolic disorders, known as metabolic 
syndrome that includes in particular abdominal obesity, hypertriglyceridemia, low levels 
of high-density lipoprotein (HDL) cholesterol, hypertension and high fasting glucose. 
Though the complete pathogenesis of metabolic syndrome is still unknown, dietary lipids 
are known to exacerbate the effects associated with this syndrome. In the case of nutrient 
excess, under normal homeostasis, adipose tissue stores the excess fat and oxidizes it 
when needed. However, when adipose tissue is not able to maintain a balance between 
storage and utilization of fat, the excessive fat spills-over to non-adipose tissues and 
accumulates there. This ectopic accumulation of fats in non-adipose tissues, leading to 
cellular dysfunction and death, is called lipotoxicity. Various transport proteins such as 
CD36/FAT, fatty acid transport proteins (FATPs) and fatty acid binding protein 
(FABPpm) act as fatty acid uptake mediators in different tissues. In this study, we have 
used a whole body knockout (KO) of fatty acid transport protein 2 (FATP2) in 
129S6/SvEv mice to understand the impact of high fat diet (60% energy from fat) 
compared with a matched low fat diet (12% energy from fat). After 12 weeks on diet, 
there was no change in the body weights of either FATP2 KO mice or 129S1/SvImJ Wild 
type (WT) mice fed high fat diet. A significant decrease in the plasma triglyceride levels 
(approximately 35%) in the FATP2 KO mice was evident compared to WT controls after 
12 weeks on high fat diets. The hepatic fatty acid content, specifically, the amount of 
saturated and monounsaturated fatty acids were significantly higher in FATP2 KO mice 
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compared to WT mice fed both diet. C16:0, C16:1, C18:1, C20:1 and C20:3 class of fatty 
acids were significantly higher in FATP2 KO mice compared to controls. The hepatic 
triglyceride content was also higher in the FATP2 KO mice compared to WT controls on 
HFD. The qPCR analysis of FATP2 KO mice livers exhibited elevated levels of FATP5, 
ACSL1 and ACSL5 genes on HFD and in the hepatocytes of FATP2 KO mice fed 
normal chow. Thus this study is important to determine the effects of diet as well as 
understanding the role of fatty acid transport proteins in the causation of obesity and 
related disease states. 
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4.1. INTRODUCTION 
Metabolic syndrome (MS) is characterized by cluster of metabolic disorders including 
abdominal obesity, dyslipidemia, hypertension and impaired fasting glucose. This cluster 
of factors may increase the risk for cardiovascular morbidity and mortality. Nutritional 
excess including consumption of high amounts of fats and carbohydrates plays a crucial 
role in the development of obesity and related diseases such as non-alcoholic fatty liver 
disease (NAFLD), insulin resistance and diabetes mellitus [86]. It is also known that type 
of diet consumed plays a significant role in the progression of these disease states rather 
than the absolute amount. Western diet is characterized by excessive amounts of 
saturated fatty acids, n-6 polyunsaturated fatty acids and trans fatty acids that exacerbate 
the conditions of obesity, diabetes and cardiovascular diseases [87]. Along with diet, 
interaction of genetic background also predisposes patients to these disease states. Thus, 
it is important to investigate the nutrient-gene interaction in response to diets high in fat 
or carbohydrate in different genetic backgrounds [88].  
 
Normal lipid partitioning requires coordinated regulation of both caloric intake and 
outflow by maintaining a balance between formation and delivery of fatty acids and 
consumption or utilization of fatty acids. Under normal conditions of excess calorie 
intake than required for anabolic and catabolic activities, fatty acids are stored in adipose 
tissue. However, when adipose tissue is no longer able to store and utilize excessive 
incoming fat, the fatty acids start accumulating in non-adipose tissues such as liver, heart 
and pancreatic cells. This ectopic accumulation of fat in non-adipose tissues leads to 
cellular and tissue dysfunction that is called lipotoxicity [89]. Ability to prevent the 
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uptake of excessive fatty acids into non-adipose tissue and directing them towards 
adipose tissue or excretion would be an attractive target to protect against lipotoxicity 
related diseases. Since transport of fatty acids is a carrier-mediated process, 
understanding the role of different transport proteins during high-energy dietary intake 
and high fat feeding is necessary to discern the etiology of lipotoxicity related diseases. 
 
Fatty acid transport proteins (FATP) are one such family of proteins that are involved in 
the cellular import and activation of long chain and very long chain fatty acids into cells 
(details provided in Chapter 1-Introduction). The most studied among these are FATP1, 
expressed in adipose tissue, muscles, brain and heart; FATP2, expressed in liver, kidney 
and small intestines; and FATP4, expressed primarily in small intestines. Studies 
involving the overexpression of FATP1 in heart lead to cardiomyopathies in transgenic 
mice [90] and deletion of FATP1 in skeletal muscle was shown to protect the KO mice 
from high fat induced insulin resistance and intramuscular accumulation of fatty acyl 
CoAs [31]. Similarly, loss of FATP4 in skin resulted in restricted dermopathy, which is a 
lethal phenotype due to dehydration and restricted movements that impairs breathing 
[38]; however, FATP4 was dispensable for fatty acid uptake when targeted exclusively in 
small intestines [40].  
 
Previously, a knockout of the FATP2 gene in mice was generated to understand the role 
of this protein in X-linked adrenoleukodystrophy [91]. It was generated by inserting a 
1100bp neomycin-resistance cassette in exon 3 of Vlcs/FATP2 gene and transfecting the 
stem cells of 129SvEv embryos. The positive chimeras were used to develop a 
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homozygous line in the 129S background and were called the Vlcs KO mice. Results 
indicated that knocking out the FATP2 gene in 129S1/SvEv mice leads to a 4-fold and 9-
fold diminution in the very long chain acyl-CoA synthetase activity (VLACS) activity in 
liver (microsomal and peroxisomal fractions) and kidney respectively. Approximately 
40% reduction in very long chain fatty acid (VLCFA) peroxisomal β-oxidation was also 
reported, without accumulation of VLCFA in those tissues [91]. Thus, the VLACS 
activity of FATP2 gene was studied but the transport activity was not considered.  
 
The current study correlates to understand the effects of FATP2-mediated fatty acid 
uptake inhibitors on a diet-induced obesity animal model discussed in the prior chapter. 
We determined the effects of high fat (60% energy from fat) and low fat (12% energy 
from fat) matched diets on the wild type 129S1/SvImJ and whole body knockout of 
FATP-2 gene in129S6/SvEv mice. Understanding the effects of HFD in a whole body 
FATP2 knockout will provide valuable information regarding the role of FATP2 in lipid 
homeostasis.  
 
Studies involving high fat feeding in 129S strain have shown that this strain develops 
features of metabolic syndrome such as obesity, hyperinsulinemia and glucose 
intolerance after several weeks of high fat feeding [92]. But the severity of development 
of these features is drastically different from the most common animal model used for 
diet-induced obesity studies, C57Bl/6 (B6) strain. B6 strain develops the same features on 
both high and low fat diets and the affect is much more severe than 129S strain [92, 93]. 
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The drastic distinctive phenotypes for both strains under similar conditions of high fat 
feeding is detailed later in discussion part.   
4.2.RESULTS 
4.2.1. Effect of high fat and low fat diets on the body weight of WT and FATP2 KO 
strain 
To understand the implications of diet on the whole body knockout of fatty acid transport 
protein-2 (FATP2) in vivo, 5 weeks old 129S1/SvImJ wild type (WT) and 129S6/SvEv 
FATP2 knockout (KO) mice were subjected to high fat (HFD) and low fat diets (LFD) 
(matched controls) for 12 weeks (n=10 for each diet treatment for each strain). Both diets 
were matched to base diets (TestDiets® Basal Diet 5755) and were lard based with HFD 
providing 60% energy from fat whereas LFD has 12% energy from fat. The calories from 
LFD were 3.87 kcal/g and from HFD were 5.21 kcal/g. All the other components of diet 
such as protein, fiber and micronutrients were balanced in both diets. The composition of 
the diets is shown in Table 4.1 and the amount of individual fatty acids present in each 
diet is represented as µmol/g and mol% in Table 4.2. As shown, both the diets are same 
except for the amount of fat present in them. These diets were provided ad libitum with 
water and changed every 2 days to prevent the oxidation of fatty acids especially in high 
fat diet. There was a significant difference in the body weight of WT and FATP2 KO 
mice fed HFD and LFD fed mice irrespective of the genotype (Figure 4.1). 
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Table 4.1: Ingredients of High Fat and Low Fat diets as obtained from TestDiet® 
# Catalog no. 58G9; *Catalog no. 58G7. High fat diet, 60% energy from fat; and low fat 
diet, 12% energy from fat 
 
Table 4.2: Fatty acid content of high fat and low fat diets. 
Fatty Acid 
Low Fat diet High Fat diet Low Fat diet High Fat diet 
μmol/g mol % 
C14:0 - 14.27 - 1.56 
C16:0 20.42 232.30 14.82 25.35 
C18:0 4.00 108.05 2.88 11.80 
ΣSFA 24.40 354.63 17.70 38.70 
C16:1 - 17.24 - 1.88 
C18:1 42.00 337.74 30.46 36.86 
C20:1 - 4.56 - 0.50 
ΣMUFA 42.00 359.54 30.46 39.24 
C18:2 69.85 193.42 50.67 21.11 
C18:3 1.62 5.30 1.18 0.58 
C20:2 - 3.30 - 0.36 
ΣPUFA 71.47 202.01 51.85 22.05 
Values are shown for fatty acid analysis done on one pellet of high fat and low fat diet 
fed to WT and FATP2 KO mice. 	  
Ingredients of Diets (type of 
macronutrient) 
High Fat Diet# 
(gm/kg) 
Low Fat Diet* 
(gm/kg) 
Dextrin (carbohydrate) 189.9331 486.2212 
Casein-Vitamin Free (protein) 267.6011 198.699 
Sucrose (carbohydrate) 63.7146 165.5825 
Corn Oil (fat) 63.715 47.3093 
RP Mineral Mix#10 (adds 1.29% fiber) 63.715 47.3093 
RP Vitamin Mix#10 (adds 1.94% sucrose) 25.486 18.9237 
Inulin (soluble fiber) 19.1144 14.1928 
Powdered Cellulose (insoluble fiber) 19.1144 14.1928 
Lard (fat) 283.147 4.2578 
Choline Chloride 2.548 1.8924 
DL-Methionine 1.9114 1.4193 
Blue/Yellow Dye Trace Trace 
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Figure 4.1: Body weights of mice fed high fat and low fat diets over a period of 12 weeks. 
Each data point represents average body weights for n=10 – 11 animals in each treatment group 
and error bars indicate the standard error mean.  	  	  
	  
Figure 4.2: Plasma Triglyceride (TAG) levels of mice fed high fat and low fat diets over a 
period of 12 weeks as determined using a commercial kit (Wako Diagnostics) after 4hrs of 
fasting. Each bar graph represents TAG levels for n=10 -11 animals in each treatment group over 
the 12 weeks period and error bars indicate the standard error mean. The data was compared 
using 2-way ANOVA (JMP 11.0) for diet and genotype interaction for a specific week. Levels 
not connected by the same letter are significantly different at p<0.05.  
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4.2.2. Changes in the metabolic parameters of both strains due to diets: 
 
Plasma Triglycerides: 
The plasma triglyceride levels were low in the FATP2 KO mice as compared to WT even 
before starting the diets (Figure 4.2). Variability in plasma triglyceride levels was 
observed over the period of 12 weeks between the two strains; however, FATP2 KO mice 
had consistently low triglyceride levels irrespective of diet. On week 13, after terminal 
bleeding via cardiac puncture, 35% and 26% reduction in the levels of plasma 
triglycerides were observed in FATP2 KO mice compared to WT fed HFD and LFD 
respectively (Table 4.3). Diets alone had no significant impact on TAG levels. 
 
Plasma Ketone Body (β-hydroxybutyrate): 
Two major classes of ketone bodies are present in the circulation: β-hydroxybutyrate 
(BHB) and acetoacetate. Since, BHB is the major ketone body in circulation, we only 
determined their levels in plasma after terminal bleed on week 13 using a commercial kit 
(Sigma Aldrich, St. Louis, MO). BHB levels were significantly higher for both genotypes 
of mice fed HFD compared to LFD (Figure 4.3).  
 
Blood Glucose: 
The blood glucose levels were determined using the Accu-Chek Aviva Plus blood 
monitoring system every week after 4hr fasting. There was no difference in the levels of 
blood glucose between the genotypes over a period of 12 weeks (Figure 4.4).  
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Figure 4.3: Plasma β-hydroxybutyrate levels (ketone body) in mice fed high fat and low fat 
diets as determined using Sigma kit after 4hrs of fasting on week 13. Each bar graph represents 
n=6 -7 animals in each treatment group. Error bars indicate the standard error mean. The data was 
compared using 2-way ANOVA (JMP 11.0) for diet and genotype interaction. Levels not 
connected by the same letter are significantly different at p<0.03.  
	  
Table 4.3: Physiological parameters of wild type and FATP2 KO mice fed high fat and low 
fat diets in week 13 after terminal bleed via cardiac puncture. 
 
Values are shown as average values for 10-12 mice ± standard error. TAGs: triglycerides; 
BHB: β-hydroxybutyrate levels (major ketone body); WT LF: wild type low fat; WT HF: 
wild type high fat; KO LF: FATP2 knockout low fat; and KO HF: FATP2 knockout high 
fat. *p<0.05 for comparison of WT with FATP2 KO mice on each diet. 
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A variability and trend was evident over the period of 12 weeks with HFD mice having 
higher glucose levels as compared to the LFD mice. After terminal bleed via cardiac 
puncture in week 13, the blood glucose levels were significantly reduced for FATP2 KO 
mice fed LFD compared to WT fed LFD (Table 4.3). The glucose levels were lower for 
HFD fed FATP2 KO mice but the difference was not statistically significant (190mg/dl 
versus 225mg/dl). 
 
Plasma Insulin: 
Insulin levels were determined in the plasma samples obtained after terminal bleeds via 
cardiac puncture in week 13 after 4hrs of fasting using Ultra sensitive Mouse Insulin 
ELISA kit (Crystal Chem Inc.). The insulin levels were higher for HFD fed mice 
compared to LFD fed mice irrespective of the genotype (Figure 4.5 and Table 4.3).  
 
Plasma Leptin: 
Leptin levels were determined in plasma samples using Mouse leptin ELISA kit 
(Millipore) after terminal bleed in week 13. No differences in the leptin levels were 
observed due to genotype alone. However, HFD feeding significantly increased leptin 
levels compared to LFD diet for both genotypes (Figure 4.6 and Table 4.3). This is 
expected due to the increase in adipose tissue and body weight for mice fed the HFD. 
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Figure 4.4: Blood glucose levels of mice fed high fat and low fat diets over a period of 12 
weeks. Each bar graph represents n=5- 6 animals in each treatment group and error bars indicate 
standard error mean. The data was compared using 2-way ANOVA (JMP 11.0) for diet and 
genotype interaction over the period of 10 weeks. Levels not connected by the same letter are 
significantly different at p<0.05.  
 
	  
Figure 4.5: Plasma Insulin levels of mice fed high fat and low fat diets on week 13 after 4hrs 
of fasting as determined using Crystal Chem Mouse Insulin ELISA kit. Each bar graph represents 
n=9-10 animals in each treatment group and error bar indicate the standard error mean. The data 
was compared using analysis ANOVA (JMP 11.0) for diet and genotype interaction. Levels not 
connected by the same letter are significantly different at p<0.03.  
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Figure 4.6: Plasma Leptin levels in mice fed high fat and low fat diets in week 13 after 4hr 
fasting as determined using Mouse Leptin ELISA kit (Millipore). Each bar graph represents n=4-
5 animals in each treatment group in week 12 after sacrifice. Error bars indicate standard 
deviation of average triglyceride levels across the experimental mean. The data was compared 
using 2-way ANOVA for diet and genotype interaction (JMP 11.0). Levels not connected by the 
same letter are significantly different at p<0.05.  	  
	  
Figure 4.7: Pictures of inner cavity (fat content) (A) of WT and FATP2 KO fed HFD and 
livers (B) of wild type and FATP2 KO mice fed high fat and low fat diet for 12 weeks. WT 
HF, wild type high fat; WT LF, wild type low fat; KO HF, FATP2 KO high fat; and KO LF, 
FATP2 KO low fat. 
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4.2.2.Tissue weights: 
After 12 weeks on diet, mice were fasted for 4hrs and then sacrificed and tissues were 
harvested. Figure 4.7 shows the pictures of inner cavity of mice (Figure 4.7A) of HFD 
fed mice and livers (Figure 4.7B) of WT and FATP2 KO mice fed high fat and low fat 
diets for 12 weeks. The liver color was much paler for mice on HFD as compared to LFD 
mice though no color difference was visible between the livers of two genotypes (Figure 
4.7B). The liver weight was higher for FATP2 KO mice on either diet compared to WT 
control (Figure 4.8). The weight of FATP2 KO liver fed HFD was 1.2 grams, that was 
significantly higher compared to WT fed HFD and LFD (0.94 and 0.83 grams) and 
FATP2 KO fed LFD (0.98grams). The visceral fat (adipose tissue) was significantly 
higher for HFD versus LFD but was not significantly different between the genotypes 
(2.09g for WT-HFD versus 1.91g FATP2 KO-HFD) (Figure 4.8). Kidney weights were 
also higher for FATP2 KO mice compared to WT (0.36g for FATP2 KO-HF and LFD 
versus 0.33 and 0.31g for WT-HF and WT-LF, respectively) (Figure 4.8). The weight of 
muscle (gastrocnemius muscle) of FATP2 KO fed LFD was significantly lower 
compared to WT fed HF and LF diets and FATP2 KO fed HFD. Overall, there was no 
difference between the WT and FATP2 KO mice on HFD and LFD phenotypically.  
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Figure 4.8: Tissue weights of mice fed high fat and low fat diets for 12 weeks. Mice were 
fasted for 4hrs and then bled terminally and tissues collected. Each bar graph represents n=10 -11 
animals in each treatment group. The data was compared using 2-way ANOVA for diet and 
genotype interaction (JMP 11.0) for different tissues. Levels not connected by the same letter are 
significantly different at p<0.05.  	  
	  
Figure 4.9: Hepatic triglyceride (TAG) content of mice fed low fat and high fat diets for 12 
weeks. Livers were collected after 4hrs of fasting and flash frozen. For triglyceride analysis, 
triglycerides were extracted from the liver tissue and subjected to Wako Diagnostics kit assay as 
per manual instructions. Each bar graph represents n=10 or 11 animals in each treatment group in 
week 12 after sacrifice and error bars indicate standard error mean. Levels not connected by the 
same letter are significantly different at p<0.05.  
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4.2.3.Hepatic lipid analysis: 
Since the liver weight of the FATP2 KO mice was significantly higher as compared to 
WT, we determined the hepatic triglyceride content of mice on either diet. Triglycerides 
(TAGs) were extracted from the livers and subjected to Wako Diagnostic kit to determine 
hepatic TAG levels in both the genotypes on each diet. Hepatic TAG content was higher 
for FATP2 KO mice compared to WT on HFD (p≤0.05) (Figure 4.9). The TAG content 
was also higher for LFD fed FATP2 KO mice compared to WT but was not statistically 
significant. The higher TAG levels correlate with the increase in the liver weights of 
FATP2 KO mice compared to WT. A significant increase in the liver triglycerides was 
seen in mice on HFD as compared to LFD, irrespective of genotype, as expected. 
 
Liver fatty acid profiles reflect the dietary fatty acid accumulation, elongation and 
desaturation of dietary fatty acids and de novo synthesis from dietary carbohydrates [94]. 
Individual fatty acid amount as well as classes of fatty acids differed significantly 
between the two genotypes on high fat and low diets. The amount of C16:0, C16:1, 
C18:1, C20:1 and C20:3 fatty acids were significantly higher in FATP2 KO fed HFD 
compared to WT on each diet whereas C18:0 was significantly reduced compared to WT 
fed HFD (Table 4.4). On comparing the specific class of fatty acids, the amount of 
saturated fatty acids (SFA), comprised of C16:0 and C18:0, was significantly higher in 
FATP2 KO (176.86µmol/g) compared to WT (148.17µmol/g) fed HFD (Table 4.4 & 
Figure 4.10A). However, there was no significant difference between the two genotypes 
on LFD. The amount of monounsaturated fatty acids (MUFA) (C16:1, C18:1 and C20:1) 
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Table 4.4: Hepatic Fatty Acid content (μmol/g) of wild type and FATP2 KO mice fed high 
fat and low fat diets for 12 weeks. 
Fatty Acid 
(µmol/g) WT LF WT HF FATP2 KO LF FATP2 KO HF 
C16:0 37.1 ± 2.7C 120.3 ± 8.7B 58.1 ± 6.0C 153.5 ± 10.4A 
C18:0 11.8 ± 0.5C 24.8 ± 1.1A 11.7 ± 0.6C 22.3 ± 1.0B 
ΣSFA 48.96 ± 3.0C 145.05 ± 9.7B 69.87 ± 6.3C 175.74 ± 11.1A 
C16:1 5.5 ± 1.1B 7.4 ± 1.2B 8.1 ± 1.7B 13.7 ± 1.1A 
C18:1 30.2 ± 3.1C 144.5 ± 12.4B 56.2 ± 9.0C 193.6 ± 12.8A 
C20:1 0.6 ± 0.03C 3.7 ± 0.4B 1.5 ± 0.3C 4.7 ± 0.4A 
ΣMUFA 36.13 ± 4.2C 155.62 ± 13.6B 65.37 ± 11.0C 212.02 ± 14.2A 
C18:2 31.0 ± 2.6B 123.7 ± 10.5A 35.33 ± 4.7B 117.0 ± 8.8A 
C18:3 0.7 ± 0.1C 3.3 ± 0.6A 1.2 ± 0.2BC 2.5 ± 0.2AB 
C20:2 0.6 ± 0.04B 2.5 ± 0.3A 0.8 ± 0.4B 2.3 ± 0.1A 
C20:3 1.4 ± 0.2C 4.0 ± 0.4B 2.1 ± 0.1C 5.7 ± 0.5A 
ΣPUFA 32.71 ± 2.8B 130.78 ± 11.4A 37.81 ± 5.0B 124.74 ± 9.6A 
C20:4 15.3 ± 1.2B 25.2 ± 1.5A 16.1 ± 0.8B 24.6 ± 1.7A 
C22:6 2.0 ± 0.4 5.1 ± 0.6 2.1 ± 0.9 5.1 ± 0.4 
ΣHUFA 15.50 ± 1.0B 29.84 ± 1.5A 16.30 ± 0.9B 27.85 ± 2.0A 
 
Data is represented as mean ± SEM for n=10 or 11 animals in each treatment group. The 
data was compared using 2-way ANOVA (JMP 11.0) for diet and genotype interaction 
for different class of fatty acids. Levels not connected by the same letter are significantly 
different at p<0.05. 
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Figure 4.10: Hepatic Fatty acid content represented as A) different class of fatty acids 
(μmol/g); and B) total mass (μg) in mice fed high fat and low fat diets for 12 weeks. Each bar 
graph represents n=10 – 11 animals in each treatment group in week 12. Error bars indicate 
standard deviation across the experimental mean. The data was compared using 2-way ANOVA 
(JMP 11.0) for diet and genotype interaction for different class of diets. Levels not connected by 
the same letter are significantly different at p<0.05. SFA: saturated fatty acids (C16:0 and 
C18:0); MUFA: monounsaturated fatty acids (C16:1, C18:1 and C20:1); PUFA: polyunsaturated 
fatty acids (C18:2, C18:3, C20:2 and C20:3); and HUFA: highly unsaturated fatty acids (C20:4 
and C22:6). 
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also followed the same trend as SFA. FATP2 KO fed HFD (212.02µmol/g) had highest 
amount of MUFA compared to WT (155.62µmol/g) fed HFD, though no significant 
difference was evident between the genotypes on LFD (65.37µmol/g for FATP2 KO; and 
36.13µmol/g for WT). There was no difference in the amount of polyunsaturated (PUFA) 
or highly unsaturated (HUFA) fatty acids between the genotypes, the only significant 
difference was due to the diets. Overall, the total lipid content was significantly higher in 
HFD mice compared to LFD mice irrespective of the genotype (Figure 4.10B). A trend 
was evident with FATP2 KO (4030.66µg) mice having higher hepatic fat content 
compared with WT (3438.67µg) fed HFD but it was not statistically significant 
(p=0.0568). Similarly, for LFD, FATP2 KO total fat content was 1408.22µg compared to 
1001.36µg in WT. 
 
The hepatic fatty acid data was also analyzed as mol% (Table 4.5) of each class of fatty 
acid relative to the total fatty acids in the sample to facilitate the assessment of the 
relative amount of fatty acids acquired from the diet or synthesized de novo. As shown in 
Table 4.5, there was no difference in the mol percent of saturated fatty acids between the 
two genotypes. Only difference was due to diets, as expected. An increased mol% of 
MUFA in FATP2 KO fed both diets indicate more SFA was converted to MUFA and 
MUFA was getting accumulated in FATP2 KO compared to WT fed each diet. PUFAs 
are not synthesized de novo in mammals and are obtained from diets. Any reflection of 
PUFA in the livers is indicative of PUFA obtained from diets. The mol% of C18:2, C18:3 
and C20:2 fatty acids (Table 4.2) in the diet correlated with the mol% of these fatty acids 
present in the liver but the livers of FATP2 KO accumulated more C20:3 fatty acid 
	  	  
86	  
Table 4.5: Hepatic Fatty Acid content (mol%) of wild type and FATP2 KO mice fed high fat 
and low fat diets for 12 weeks. 
Fatty Acid  
(mol%) 
WT LF WT HF FATP2 KO LF FATP2 KO HF 
C16:0 27.68 ± 0.3B 26.00 ± 0.3C 31.26 ± 0.8A 28.29 ± 0.3B 
C18:0 9.11 ± 0.5A 5.47 ± 0.2C 6.77 ± 0.7B 4.21 ± 0.2C 
ΣSFA 36.79 ± 0.7A 31.47 ± 0.4B 38.04 ± 1.4A 32.50 ± 0.4B 
C16:1 3.87 ± 0.5A 1.54 ± 0.2C 3.81 ± 0.4A 2.52 ± 0.1B 
C18:1 22.14 ± 0.9C 30.95 ± 0.2B 28.28 ± 1.8B 35.70 ± 0.4A 
C20:1 0.43 ± 0.02C 0.78 ± 0.02AB 0.69 ± 0.07B 0.85 ± 0.02A 
ΣMUFA 26.32 ± 1.4C 33.30 ± 0.34B 32.60 ± 2.3B 39.10 ± 0.5A 
C18:2 23.00 ± 0.5B 26.54 ± 0.3A 18.42 ± 0.6D 21.40 ± 0.4C 
C18:3 0.40 ± 0.04 0.64 ± 0.1 0.47 ± 0.0 0.42 ± 0.01 
C20:2 0.46 ± 0.07AB 0.52 ± 0.03A 0.25 ± 0.0B 0.38 ± 0.0AB 
C20:3 1.08 ± 0.2AB 0.84 ± 0.03B 1.23 ± 0.1A 1.03 ± 0.03AB 
ΣPUFA 24.31 ± 0.6B 28.02 ± 0.4A 19.80 ± 0.6D 22.80 ± 0.4C 
C20:4 11.63 ± 0.6A 5.54 ± 0.2C 9.18 ± 0.7B 4.55 ± 0.2C 
C22:6 - 1.15 ± 0.1 - 1.01 ± 0.03 
ΣHUFA 11.63 ± 0.6A 6.60 ± 0.3C 9.18 ± 0.7B 5.40 ± 0.2C 
 
Data is represented as mean ± SEM for n=10 or 11 animals in each treatment group. The 
data was compared using 2-way ANOVA (JMP 11.0) for diet and genotype interaction 
for different class of fatty acids. Levels not connected by the same letter are significantly 
different at p<0.05. 
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on both HFD and LFD compared to WT on each diet but it was not statistically 
significant. This suggests abnormality in the desaturase activity for the conversion of 
C18:2 to synthesize C20:4. This was reflective in the significantly reduced levels of 
C20:4 in FATP2 KO fed LFD compared to WT fed LFD. Overall, PUFA were higher in 
WT fed HFD and LFD compared to FATP2 KO fed HFD and LFD. Though there was no 
difference in HUFA between the genotypes fed HFD but the FATP2 KO had 
significantly lower levels of HUFA compared to WT on LFD suggesting a reduction in 
the synthesis and desaturation activity in FATP2 KO fed LFD.  
 
4.2.4.Expression of FATP and ACSL genes in liver 
Since the fatty acid composition of livers was high for FATP2 KO-HFD, we evaluated 
the expression of fatty acid transport proteins in the liver samples of the mice fed 
different diets. Liver predominantly expresses the FATP2, FATP5, ACSL1 and ACSL5 
genes [23, 95]. Initially, we determined the basal levels of expression of FATP and 
ACSL genes in the primary hepatocyte samples of FATP2 KO and WT mice on normal 
chow diet using quantitative PCR. As expected, the expression levels of FATP2 gene 
were 93% reduced in KO strain as compared to the WT (p<0.0001) (Figure 4.11A). On 
the other hand, the expression of FATP5 gene was 24% higher in FATP2 KO strain as 
compared to WT (p<0.02). The expression level of ACSL1 and ACSL5 genes were also 
higher, 28% and 45% respectively, in FATP2 KO strain as compared to WT (p≤0.02) 
(Figure 4.11B).  
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A similar expression pattern was observed for WT and FATP2 KO mice fed high fat and 
low fat diets (Figure 4.12). In WT mice, there is an apparent suppressive effect of FATP2 
expression due to the HFD. FATP5 expression, in contrast, is increased by HFD feeding 
in both genotypes. There is an additive increase in FATP5 expression due to both 
genotype and diet. The ACSL1 gene has increased gene expression due to both genotype 
and diet effects. There is suppression in the expression of ACSL5 gene on high fat diet in 
both genotypes compared to LFD feeding. Thus it appears that deletion of FATP2 gene 
likely causes a compensatory increase in FATP5 and ACSL1 that may account for the 
increase in TAG levels in liver.  
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Figure 4.11: Expression of A) Fatty Acid Transport Proteins (FATPs); and B) Long-chain 
Acyl-CoA synthetase (ACSL) genes in primary hepatocytes of wild type (129S1/SvImJ) and 
FATP2 KO (129S6/SvEv) fed normal chow diet. Quantitative PCR was used to determine the 
expression of different genes. Data is expressed relative to β-actin, a housekeeping gene as mean 
± SE for n=3 samples done in triplicates. The data was compared using ANOVA (JMP 11.0) 
followed by Student’s t-test. Levels not connected by the same letter are significantly different. 
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Figure 4.12: Expression levels of different FATP and ACSL genes in liver samples of wild 
type (129S1/SvImJ) and FATP2 KO (129S6/SvEv) mice fed high fat and low fat diets for 12 
weeks. Quantitative PCR was used to estimate the expression of different genes and is expressed 
relative to β-actin. The values are represented as mean ± SE for n=3 samples done in triplicates. 
The data was compared using 2-way ANOVA for diet and genotype interaction for expression of 
different genes (JMP 11.0) followed by Student’s t-test. Levels not connected by the same letter 
are significantly different at p<0.05. The two bottom panels show the enlarged view of FATP and 
ACSL gene not visible in top panel. 
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4.2.5.Fecal lipid analysis 
In order to determine the influence of dietary intake on the absorption of fatty acids, fecal 
lipid profiles were analyzed. The total lipid content in fecal samples of FATP2 KO fed 
HFD mice were significantly higher compared to WT fed HFD (Figure 4.13). However 
there was no difference between the genotypes on LFD. On comparing the specific class 
of fatty acids, SFA (C14:0, C15:0, C16:0, C18:0, C20:0, C22:0 and C24:0) were most 
abundant in the fecal samples as compared to MUFA (C16:1, C18:1, C20:1 and C22:1), 
PUFA (C18:2 and C20:3) and HUFA (C20:4) (Table 4.6 and Table 4.7). The presence of 
increased mol% of C20:4 (HUFA) in the samples of FATP2 KO fed LFD compared to 
WT suggests C20:4 was synthesized but was not absorbed efficiently by FATP2 KO 
mice (Table 4.6). Same trend was evident between the genotypes on HFD as well but was 
not statistically significant. Similarly, other very long chain fatty acids (C22:0, C22:1 and 
C24:0) were also elongated from fatty acids in the diet or synthesized de novo but were 
not absorbed because of their presence in feces.  
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Figure 4.13: Total fecal fatty acid mass in micrograms of WT and FATP2 KO mice fed high 
fat and low fat diets for 12 weeks. Each bar graph represents n=3-8 animals in each treatment 
group. Error bars indicate standard deviation across the experimental mean. The data was 
compared using ANOVA (JMP 11.0) for diet, genotype and diet*genotype interaction. *p=0.05 
for genotype difference on HFD. 	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Table 4.6: Fatty acid profile (in mol%) of lipids extracted from feces of WT and FATP2 KO 
fed high fat and low fat diets. 
Fatty Acids 
(mol%) WT LF WT HF FATP2 KO LF FATP2 KO HF 
C14:0 2.86 ± 0.1A 1.44 ± 0.1B 2.90 ± 0.3A 1.20 ± 0.1B 
C15:0 1.96 ± 0.6 1.72 ± 0.6 2.20 ± 0.3 1.23 ± 0.3 
C16:0 25.89 ± 1.2B 23.56 ± 0.6B 30.60 ± 1.1A 24.00 ± 1.1B 
C18:0 12.26 ± 5.4B 38.56 ± 3.5A 22.54 ± 2.7B 44.79 ± 1.6A 
C20:0 3.74 ± 1.1A 1.72 ± 0.2B 3.91 ± 0.3A 2.49 ± 0.2B 
C22:0 2.74 ± 0.8A 1.08 ± 0.2B 2.72 ± 0.1A 1.1 ± 0.1B 
C24:0 1.00 ± 0.2A 0.40 ± 0.1B 1.00 ± 0.1A 0.42 ± 0.1B 
ΣSFA 50.47 ± 9.2C 68.50 ± 3.1AB 65.52 ± 2.9B 75.21 ± 2.5A 
C16:1 5.70 ± 1.4A 2.71 ± 0.4B 3.24 ± 0.6B 2.02 ± 0.3B 
C18:1 20.63 ± 5.6A 17.85 ± 1.6AB 14.46 ± 0.7AB 13.80 ± 1.6B 
C20:1 3.00 ± 1.8AB 1.34 ± 0.1AB 3.00 ± 1.0A 0.74 ± 0.1B 
C22:1 2.77 ± 1.04A 1.00 ± 0.2B 1.74 ± 0.2AB 0.83 ± 0.4B 
ΣMUFA 32.08 ± 4.2A 22.90 ± 2.0B 22.41 ± 1.6B 17.31 ± 1.8B 
C18:2 14.72 ± 4.4A 7.85 ± 1.1B 9.02 ± 1.4B 6.65 ± 1.0B 
C20:3 0.46 ± 0.2 0.32 ± 0.1 0.60 ± 0.1 0.3 ± 0.1 
ΣPUFA 15.18 ± 4.6A 8.00 ± 1.2B 9.47 ± 1.4B 6.81 ± 0.9B 
C20:4 1.28 ± 0.4B 0.43 ± 0.1C 2.06 ± 0.2A 0.5 ± 0.1C 
ΣHUFA 1.28 ± 0.4B 0.43 ± 0.1C 2.06 ± 0.2A 0.5 ± 0.1C 
Data is represented as mean ± SEM for n= 3 - 8 animals in each treatment group. The 
data was compared using 2-way ANOVA (JMP 11.0) for diet and genotype interaction 
for different class of fatty acids. Levels not connected by the same letter are significantly 
different at p≤0.05. 
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Table 3.7: Fatty acid profile (in µmol/g) of lipids extracted from feces of WT and FATP2 
KO fed high fat and low fat diets. 
Fatty Acids 
(µmol/g) WT LF WT HF FATP2 KO LF FATP2 KO HF 
C14:0 1.06 ± 0.1 0.96 ± 0.1 0.74 ± 0.1 0.86 ± 0.1 
C15:0 0.71 ± 0.2 1.11 ± 0.4 0.58 ± 0.1 0.86 ± 0.1 
C16:0 9.60 ± 1.4B 15.93 ± 1.5A 7.84 ± 0.4B 17.62 ± 1.5A 
C18:0 4.19 ± 1.8C 26.16 ± 3.0B 6.00 ± 1.0C 32.68 ± 2.3A 
C20:0 1.29 ± 0.3AB 1.16 ± 0.2B 1.01 ± 0.1B 1.81 ± 0.2A 
C22:0 0.95 ± 0.2 0.69 ± 0.1 0.67 ± 0.1 0.80 ± 0.1 
C24:0 0.35 ± 0.05 0.25 ± 0.04 0.25 ± 0.02 0.30 ± 0.04 
ΣSFA 18.15 ± 2.8B 46.30 ± 4.5A 17.00 ± 1.4B 54.95 ± 3.9A 
C16:1 2.24 ± 0.9A 1.93 ± 0.4A 0.81 ± 0.1B 1.52 ± 0.3AB 
C18:1 8.07 ± 3.2AB 12.09 ± 1.4A 3.75 ± 0.3B 10.03 ± 1.3A 
C20:1 1.03 ± 0.6 0.89 ± 0.1 0.73 ± 0.2 0.53 ± 0.1 
C22:1 0.95 ± 0.3 0.64 ± 0.1 0.43 ± 0.1 0.55 ± 0.2 
ΣMUFA 12.29 ± 3.4A 15.56 ± 1.9A 5.73 ± 0.4B 12.57 ± 1.5A 
C18:2 5.71 ± 2.3AB 5.55 ± 1.1A 2.30 ± 0.3B 5.00 ± 0.8A 
C20:3 0.19 ± 0.1 0.19 ± 0.03 0.15 ± 0.02 0.23 ± 0.1 
ΣPUFA 5.90 ± 2.4AB 5.64 ± 1.1A 2.42 ± 0.3B 5.12 ± 0.8A 
C20:4 0.52 ± 0.2 0.31 ± 0.04 0.54 ± 0.1 0.38 ± 0.1 
ΣHUFA 0.52 ± 0.2 0.31 ± 0.04 0.54 ± 0.1 0.38 ± 0.1 
Data is represented as mean ± SEM for n= 3 - 8 animals in each treatment group. The 
data was compared using 2-way ANOVA (JMP 11.0) for diet and genotype interaction 
for different class of fatty acids. Levels not connected by the same letter are significantly 
different at p≤0.05. 
  
	  	  
95	  
4.3. DISCUSSION 
In this study we initiated a biochemical and genetic profile of elimination of fatty acid 
transport protein-2 in a mouse model. There was no difference in the body weights 
between the two genotypes on either diet. However, the plasma triglyceride levels were 
reduced to almost 35% and 26% in FATP2 KO mice on HFD and LFD, respectively, 
compared to WT. FATP2 transport protein is predominantly expressed in small intestines 
[33] and liver [23]. Thus, the reduction in plasma TAGs could be due to a reduced ability 
of KO animals to absorb fat and pack them as TAGs in chylomicrons and release them 
into circulation. Other serological parameters including as glucose, insulin and leptin 
were also similar between the two genotypes on either diets. We measured increased 
levels of ketone body (BHB) in the circulation of FATP2 KO fed HFD and LFD 
compared to WT. Ketone bodies (BHB and acetoacetate) are produced in response to 
increased fatty acid oxidation in the state of decreased glucose production to meet the 
energy crisis in tissues that do not take up fatty acids such as brain [96]. Increased levels 
of BHB in FATP2 KO fed LFD mice suggest that stored fat in the liver is being oxidized 
and converted into ketone bodies.   
 
The hepatic lipid analysis of FATP2 KO and WT genotypes indicated occurrence of 
steatosis in the high fat diet fed mice. The livers of FATP2 KO mice were significantly 
heavier in weights and paler as compared to WT on high fat diet. The hepatic TAG 
content and total fat mass was also higher in FATP2 KO fed either diet. FATP2 KO mice 
fed HFD had higher amounts of SFA and MUFA in their livers specifically C16:0, C16:1, 
C18:1, C20:1 and PUFA, C20:3. Quantitative PCR analysis of livers exhibited elevated 
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levels of ACSL1, ACSL5 and FATP5 genes in FATP2 KO fed HFD mice. All these 
features indicate towards the state of steatosis exhibited on high fat feeding in mice [97].  
 
In a recent study, 12 weeks of high fat diet feeding with a liver specific adeno-associated 
viral (AAV) knockdown of FATP2 gene at week 6 led to a significant reduction in the 
liver TAGs and improvement in the fasting glucose and insulin levels in high fat diet fed 
FATP2 knockdown animals [35]. Improvement in hepatosteatosis in liver specific AAV 
assisted FATP2 knockdown could be a transient effect as compared to a whole body 
knockout as in our case where animals overcame the loss of FATP2 by compensatory 
expression of FATP5, ACSL1 and ACSL5.   
 
The accumulation of TAGs in the liver occurs due to an imbalance between fatty acid 
acquisition and its removal [98]. Thus the TAGs in the liver is a complex interaction 
between 1) FFA uptake obtained by lipase action on TAGs obtained from adipose tissue 
or in circulation; 2) de-novo lipogenesis of fatty acids; 3) fatty acid oxidation; and 4) 
removal of fatty acids as very low density lipoprotein (VLDL) [98, 99]. Overexpression 
of FATP5, ACSL1 and ACSL5 could explain the increased accumulation of TAGs in the 
livers of FATP2 knockout mice fed HFD. Studies involving knockout of FATP5 gene 
have shown a reduction in LCFA uptake in the hepatocytes of FATP5 KO mice fed 
normal chow diet. A 59% reduction in the hepatic TAG levels was also observed for 
FATP5 KO mice compared to WT controls [100]. Similarly, adenoviral associated 
overexpression of ACSL1 in liver [101] and overexpression of ACSL5 in rat hepatocytes 
have also shown increased accumulation of TAGs [102]. Thus, these studies indicate that 
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FATPs and ACSLs direct the fatty acid metabolism towards TAG synthesis and storage 
rather than β-oxidation. This is in correlation with our data, which demonstrated that 
overexpression of FATP5, ACSL1 and ACSL5 in FATP2 KO, fed HFD mice leads to 
increased TAG accumulation in livers.  
 
Hepatic FFA profile also indicated towards an increased levels of C16:0, C18:1, C20:1 
and C20:3 in the FATP2 KO animals. Results from a study evaluating the fatty acid 
composition of livers of mice fed high fat diets and 40% CCl4 –vegetable oil solution to 
generate NAFLD and controls (normal chow diet) exhibited increased levels of C16:0, 
C18:0 and C20:3 and decreased levels of C18:1,C18:2 and C18:3 in NAFLD group. Also 
increased levels of SFA and decreased MUFA was evident in NAFLD group as 
compared to control [97]. However, in our study, though C16:0, C16:1, C18:1 and C20:3 
were significantly high in FATP2 KO animals, C18:0 was high in WT fed HFDs. Also, 
there was a significant increase in both SFA and MUFA with no changes in PUFA or 
HUFA in FATP2 KO group compared to WT fed HFD. This is a pattern we would expect 
if de novo lipogenesis has increased fatty acid synthase (FAS) or the increased levels of 
C16:0 could be due to high amount of lard present in the HFD. In a study involving the 
comparison of FA in plasma of NASH patients with controls, increased levels of C16:0 
and C18:1 was evident [97]. This is in correlation with our data which shows increased 
C16:0 and C18:1 in liver of FATP2 KO animals.  
 
Another study used spontaneous hypertensive rats (SHR), specifically SHR/NDcp, a sub-
strain of SHR/NIHcp (SHR/ National Institute of Health-corpulent rats) as a model for 
	  	  
98	  
metabolic syndrome and determined their hepatic fatty acid composition on standard diet. 
This rat model exhibited increased levels of C16:0, C16:1, C18:1 and C20:3 similar to the 
FA profile evident in our FATP2 KO HFD animals. As per this study, the increased 
levels of C16:0, C18:1 and C16:1 were due to increased de novo fatty acid synthesis and 
TAG synthesis with a decrease in β-oxidation in the livers of SHR/NDcp animals [103, 
104]. Over-accumulation of C20:3 in SHR/NDcp animals could be due to the 
abnormality in the rate limiting step involving delta-5 and delta-6 desaturase in the 
conversion of C20:3 to C20:4 [104, 105]. Further experiments are needed to validate this 
for our study.  
 
An important factor to be considered in the present study is the strain of mice used for 
FATP2 KO and WT diet studies. All diet-induced obesity studies and loss or gain of 
functions of FATP and ACSLs discussed above were carried out in C57Bl/6 (B6) mice. 
However, the whole body FATP2 KO and matched WT in our study are in 129S 
background. Recent studies have shown significant differences in the weight gain and 
expression pattern of genes involved in lipid metabolic pathways between B6 and 129S 
strains on high fat feeding [92, 106-108]. Biddinger et al. [92] reported that both strains 
C57Bl/6 (B6) and 129S6/SvEvTac (129S) mice fed high fat diet for 18 weeks develop 
features of metabolic syndrome, notably, obesity, hyperinsulinemia and glucose 
intolerance. However, B6 developed these features on low fat diets as well. Both strains 
had reduced serum TAGs, hepatic steatosis and hypercholesterolemia on HFD but the 
severity of steatosis were higher in B6 strain with larger increases in LDL cholesterol as 
well. B6 mice were also more obese, glucose intolerant, hyperinsulinemic and 
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hyperleptinemic than 129S mice. Comparing the expression of genes involved in lipid 
metabolic pathway, it was reported that B6 mice express SCD1 and SREBP-1c genes at 
much higher levels on HFD compared to 129S strain. The levels of insulin were also 
almost 5-fold higher in B6 mice compared to 129S mice [92]. Another study involving 
targeted proteomics in B6 and 129S reported that high fat feeding alters proteins involved 
in fatty acid biosynthetic pathway, β-oxidation and glucose metabolism after 6-12 weeks 
on diet. The lipid biosynthetic genes such as fatty acid synthase (FAS) and acetyl-CoA 
carboxylase beta (ACACB) showed increased protein abundance in B6 mice whereas the 
same were decreased in 129S strain. Other genes with opposite trends in each strain 
included the β-oxidation genes ACOX1 (peroxisomal acyl-CoA oxidase 1) and ECHB 
(enoyl CoA hydratase, beta subunit –alias acetyl CoA acyltransferase), which were 
higher in 129S strain. Thus, high fat feeding activated peroxisomal β-oxidation in B6 
animals whereas lipogenesis pathway operates in 129S strains under same conditions 
[108]. This shows that genetic background plays a significant role in the progression of 
disease state under same conditions of high fat feeding.  
 
Fecal lipid fatty acid profile suggests that saturated fatty acids were the most abundant 
class of fatty acid to be excreted. Very long chain fatty acids (C20:4, C22:0, C22:1 and 
C24:0) secreted in the feces were either synthesized de novo or elongated from other 
dietary fatty acids were not absorbed. The total amount of fecal fat excreted was 
significantly higher for FATP2 KO fed HFD compared to WT but was not statistically 
significant for LFD fed mice. This is what we expect from FATP2 KO mice on HFD so 
that they are protected from weight gain. However, FATP2 KO in our study gained body 
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weight equivalent to WT fed HFD. This could be due to hyperphagic nature of FATP2 
KO mice but this is just estimation since food intake by individual group was not 
measured in this study.  
 
Thus this study shows that on high fat diet, FATP2 KO mice have reduced plasma 
triglycerides but livers are steatotic in the absence of FATP2, likely due to compensatory 
expression of FATP5, ACSL1 and ACSL5 genes. Hepatic fat is likely partitioned into the 
metabolic route of TAG synthesis and storage in FATP2 KO animals leading to steatosis. 
Further exacerbation is probably caused by the disequilibrium in de novo lipid synthesis 
(increased C16:0, C16:1, C18:1, C20:1 and C20:3 fatty acids) and fatty acid oxidation 
(increased ketone body levels) in liver of FATP2 KO animals. Also, FATP2 KO has 
increased fat elimination through feces but no change in body weights compared to WT. 
However, the possibility of these metabolic changes occurring because of the background 
strain of the mice cannot be ruled out either.  
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4.4. MODEL SHOWING THE EFFECT OF HIGH FAT DIET ON WHOLE BODY 
KNOCKOUT OF FATP2 GENE 
Increased amounts of fat-rich diets along with a sedentary lifestyle are considered the 
major players in causing weight gain and related diseases. The condition is worsened 
when excess fatty acids start accumulating in non-adipose tissue leading to organ failure 
and cellular dysfunction. The roles of the fatty acid transport proteins in the 
pathophysiology of these disease states is important to understand the etiology of these 
diseases. This is the first study that describes the effect of high fat and low fat diets in 
whole body knockout of FATP2 in mice. FATP2 is predominantly expressed in small 
intestines, liver and kidneys. The model depicting the fate of fatty acids after high fat 
feeding in WT and FATP2 KO mice is exhibited in Figure 4.14 and 4.15, respectively. In 
our studies, we have shown that after 12 weeks on high fat diet, FATP2 KO mice have 
reduced plasma triglyceride levels as compared to wild type mice. This is suspected to be 
due to the inability of FATP2 KO mice to absorb fat across gut in the absence of 
transport protein, FATP2. Secondly, an overexpression of FATP5, ACSL1 and ACSL5 
transport proteins is evident in the livers of knockout animals, probably compensating for 
the loss of FATP2. The overexpression of the other transport proteins resulted in hepatic 
steatosis in KO animals due to increased levels of hepatic triglycerides reflected in the 
amount of saturated and monounsaturated fatty acids. Also, FATP2 KO mice 
demonstrated increased β-oxidation as evident by increase in the levels of ketone bodies 
in circulation of mice fed high fat and low fat diets. Further experiments are required to 
further dissect specific mechanisms active in the livers of FATP2 KO mice leading to 
steatosis coincident with reduced TAGs in circulation.  
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Figure 4.14: Effect of high fat diet on wild type (129S1/SvImJ) mice. Metabolic changes in 
lipid metabolism as evident in small intestines (A), liver (B) and release of fatty acid metabolites 
in circulation (C) of wild type mice fed high fat diets for 12 weeks. Ingestion of HFD in WT leads 
to increased absorption of fat across gut and thus increased levels of plasma triglycerides in the 
circulation. The action of lipoprotein lipase causes release of fatty acids from TAGs in circulation 
that are taken up by liver with the help of transport proteins FATP2 and FATP5. The uptake and 
activation of fatty acids by FATPs and ACSLs (ACSL1 and ACSL5) causes accumulation of fat 
in the liver leading to steatosis. FA oxidation is also increased in liver as evidenced by increased 
levels of ketone bodies in the circulation. FATP2: fatty acid transport protein-2; TAG: 
triglycerides; LPL: lipoprotein lipase; SFA: saturated fatty acids; MUFA: mono-unsaturated fatty 
acids; PUFA: poly-unsaturated fatty acids; HUFA: highly unsaturated fatty acids; and ACSL: 
long chain acyl-CoA synthetase.  
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Figure 4.15: Effect of high fat diet on whole body FATP2 knockout gene in 129S6/SvEv 
mice. Metabolic changes in lipid metabolism as evident in small intestines (A), liver (B) and 
release of fatty acid metabolites in circulation (C) of whole body knockout FATP2 mice fed high 
fat diets for 12 weeks. Ingestion of HFD in FATP2 KO animals leads to decreased absorption of 
fat across gut and thus reduced levels of plasma triglycerides in the circulation. Liver takes up 
fatty acids from the circulation due to overexpression of FATP5 and directs them towards storage 
pathway due to overexpression of ACSL1 and ACSL5 leading to steatosis in KO animals. FA 
oxidation is also increased in liver as evidenced by increased levels of ketone bodies in the 
circulation. FATP2: fatty acid transport protein-2; TAG: triglycerides; LPL: lipoprotein lipase; 
SFA: saturated fatty acids; MUFA: mono-unsaturated fatty acids; PUFA: poly-unsaturated fatty 
acids; HUFA: highly unsaturated fatty acids; and ACSL: long chain acyl-CoA synthetase. 
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Chapter 5 
SUMMARY AND FUTURE DIRECTIONS 	  
In summary, the present research confirms the role of CB5 as a FATP2-mediated fatty 
acid uptake inhibitor. CB5 is efficacious in inhibiting the transport of specific class of 
fatty acid and is protective against palmitate-induced lipoapoptosis. Pharmacokinetic 
analysis of CB5 and CB16.2 (another small molecule inhibitor) shows that these 
compounds are not toxic in-vitro and in-vivo, well tolerated and stable in different 
solvents. Finally, mice orally administered with CB5 or CB16.2 demonstrated reduced 
absorption of labeled oleate across gut and were detected in plasma samples as soon as 30 
min after administration. This adds to their potential as a small molecule inhibitor or a 
therapeutic in making. However, further in-vivo experiments needs to be designed to 
understand the effect of these inhibitors on the uptake of fatty acids in tissues expressing 
FATP2 gene such as liver.  
 
In the current study, administration of CB5 or CB16.2 was accompanied by tyloxapol, a 
lipase inhibitor, which prevents the breakdown of triglyceride containing chylomicrons in 
the circulation by lipases and thus prevents the uptake of fatty acid by tissues such as 
liver, pancreas and adipose tissue. The ability of these inhibitors to prevent the uptake of 
labeled oleate in tissues expressing FATP2 such as liver and pancreas needs to be 
investigated to demonstrate their potential as a therapeutic in complex metabolic system. 
We expect these compounds to be useful in preventing or resolving obesity. Other weight 
reduction drugs available in the market such as Orlistat work by reducing uptake and 
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removal of the excessive fat through feces. Whether the small molecular inhibitors in the 
present study remove excessive fat through feces or re-route them to the storehouse of 
fat, adipose tissue, still needs to be elucidated. 
 
The utility of CB5 and CB16.2 as inhibitors can be established using diet-induced obesity 
models. Prior to using diet-induced obesity models, we have used whole body knockout 
of FATP2 gene in 129S mice to understand the implications of diet and loss of FATP2 
gene on lipid metabolism. Whole body knockout of FATP2 gene in 129S mice resulted in 
reduced absorption of triglycerides across the gut due to loss of FATP2 gene in small 
intestines. The reduction in the levels of plasma triglycerides could be due to the reduced 
formation of chylomicrons. The compensatory expression of other transport proteins in 
the small intestines of FATP2 KO animals due to the loss of FATP2 gene needs to be 
determined. 
 
Lower levels of plasma triglycerides could also be due to reduction in very low-density 
protein (VLDL) secretion from the liver. The secretion of VLDL-TAGs from the liver is 
dependent on its ability to take up dietary fat from circulation and a balance between de 
novo synthesis and fatty acid oxidation. VLDL-TAG secreted in the circulation are 
subjected to lipoprotein lipase-mediated lipolysis and taken up by peripheral tissues. 
Experiments are required to determine the levels of serum lipase and their contribution, if 
any, in the clearing VLDL-TAGs quickly and thus leading to their reduction in 
circulation.  
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We have shown that loss of FATP2 gene in liver in KO mice was compensated by over 
expressing other transport proteins (FATP5, ACSL1 and ACSL5). This resulted in 
increased accumulation of hepatic triglycerides; and saturated and monounsaturated fatty 
acids (C16:0, C16:1, C18:1, C20:1 and C20:3). The expression of genes involved in 
lipogenesis such as fatty acid synthase (FAS), acetyl-CoA carboxylase-1 (ACC1), 
stearoyl-CoA desaturase-1 (SCD1), elongase 6 and transcriptional regulators PPAR-
gamma and SREBP-1c; and in fatty acid oxidation such as carnitine palmitoyltransferase 
1a (CPT1a), acyl-CoA oxidase-1 (ACOX1) and PPAR-alpha in adipose tissue and liver 
needs to be determined. This will help dissect the specific pathway leading to steatosis in 
the livers of FATP2 KO mice. 
 
Studies have shown that overexpression of ACSL1 and ACSL5 direct the lipid 
metabolism pathway towards TAG storage rather than clearing circulating fatty acids 
[101]. Overexpression or knockout studies using labeled or radioactive fatty acids can be 
carried out in the hepatocytes isolated from KO animals to determine the role of ACSL1 
and ACSL5 in TAG storage and synthesis. Similarly, label can be used determine the 
conversion of specific fatty acids to their CoA derivatives in liver to determine the 
specific pool of complex lipids that utilize them.  
 
Thus, present research provides a base for future research to better understand the role of 
transport proteins in the etiology of disease caused by abnormalities in lipid metabolism. 
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Chapter 6 
MATERIALS AND METHODS: 
6.1.Materials: 
CB5 (2-benzyl-3-(4-chlorophenyl)-5-(4-nitrophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-
one) and its analogs were purchased from ChemBridge Corporation (San Diego, CA, 
USA). Fluorescent fatty acid analog C1-BODIPY-C12 (4,4-Difluoro-5-Methyl-4-Bora-
3a,4a-Diaza-s-Indacene-3-Dodecanoic Acid) (Catalogue no. D-3283), BODIPY-FL-C5 
(4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-Indacene-3-Pentanoic Acid) and 
BODIPY-FL-C16 (4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-Indacene-3-
Hexadecanoic Acid) were purchased from Molecular Probes/Invitrogen (Eugene, OR, 
USA). First-generation antipsychotic drug Haloperidol (H1512), second-generation drugs 
Clozapine (C6305) and Risperidone (R3030); 13C labeled oleic acid (catalog no. 490431) 
and tyloxapol (catalog no. T0307) were purchased from Sigma Aldrich. Olanzapine 
(O253750) was purchased from Toronto Research Chemicals (Ontario, Canada) and 
Quetiapine purchased from Key Organics/BIONET (External ID: KS-1099). Pancreatic 
lipase inhibitor, Orlistat, was a gift from GlaxoSmithKline (60mg per capsule). Palmitic-
acid (PA) (P-0500) was purchased from Sigma and 50mM stock prepared in 100% 
ethanol. Fatty acid- free and nuclease, protease-free Bovine Serum Albumin (BSA) was 
purchased from CalBiochem (Cat. No. 126609). Verapamil, 0.1M PBS (pH 7.4), 10mM 
NADPH (freshly prepared in PBS), acetonitrile, human and mouse (Balb-C) microsomes 
(as used by Kansas University). 
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6.2.Cell Culture and Reagents: 
HepG2 cells (ATCC, HB- 8065) were obtained from the American Type Culture 
Collection and were cultured and maintained in Earl’s Minimum Essential Medium 
(MEM/EBSS) supplemented with 10% fetal bovine serum (FBS) at 5%CO2 and 37°C. 
Cells were plated at a density of 0.8x106 cells per well on a black/clear 96-well plate (BD 
Biosciences). 
Caco-2 cells (ATCC, HTB- 37) were maintained in Earl’s minimal essential medium 
(MEM) with 20% FBS at 5% CO2 and 37°C. For growth and differentiation, the BD 
Biosciences Intestinal Epithelium Differentiation Media Pack (BD Biosciences, Franklin 
Lakes, NJ, USA) was used. Cells were plated in basal seeding medium at a density of 
0.8x106 cells/well on a collagen-coated black/clear 96-well plate (BD Biosciences). After 
72 h in culture, the basal seeding medium was removed and Entero-STIM medium 
(Thermo Fisher Scientific, Inc., New York, NY, USA) was added to each well. Both 
media contained mito-serum extender.  
 
INS-1E cells (generously provided by Pierre Maechler, Ph.D., University Medical Center 
of Geneva 4, Switzerland) were cultured at 37°C in a humidified atmosphere containing 
5% CO2 in complete medium composed of RPMI 1640 (Thermo Fisher Scientific, Inc.) 
supplemented with 5% heat-inactivated fetal calf serum, 1mM sodium pyruvate, 50 µM, 
2-mercaptoethanol and 10mM HEPES as described [109]. The maintenance culture was 
passaged once a week by gentle trypsinization, and cells were seeded in 96-well collagen 
coated black/clear plate at a density of 0.2x106 cells per well and used for 
experimentation after 96h. 
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C2C12 cells  (ATCC, CRL-1772) were maintained in Dulbecco modified Eagle medium 
(DMEM) containing 10% fetal bovine serum (FBS) and 2 mM of L-glutamine at 37°C 
and 5% CO2. For differentiation, cells were plated in differentiation medium (DMEM 
containing 10% horse serum) at a density of 0.8x106 cells per well on a black/clear 96-
well plate (BD Biosciences) for 96h. 
 
De-identified human adipocytes (generously provided by Susan K. Fried, Ph.D., Boston 
University, School of Medicine) were seeded in 96-well black/clear plates at a density of 
0.015x106 cells per well and then maintained in propagation media containing modified 
MEM, Alpha Modification, with L-Glutamine, Ribo/Deoxyribonucleosides (HyClone 
Laboratories, GE Healthcare Life Sciences, Logan, Utah, USA) and 10% FBS. For 
differentiation into adipocytes, cells were treated with propagation media supplemented 
with IBMX and rosiglitazone alone for 6 days. After 6 days, the media was changed to 
propagation media without IBMX and rosiglitazone until lipid droplets were obvious 
upon microscopic examination (up to 6 days).  
 
Primary hepatocytes were isolated from 129S1/SvImJ wild type mice between 10-12 
weeks of age using a modified protocol from [110]. Briefly, a mouse was anesthetized 
using 30% isoflurane in polyethylglycol and pinned down on its back. His abdominal 
cavity was exposed, vena porta located and a surgical silk thread passed beneath the 
porta. An overhead knot was then made and using forceps, the vena porta was 
straightened out and vein was cannulated using an Insyte Autoguard catheter (24 GA, 0.7 
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x 19 mm, BD Biosciences). Needle was retracted and removed and the thread tied 
securely to hold the catheter. The liver was then flushed with tris-buffered saline (TBS-
154mM NaCl, 10mM Trizma Base salt) to remove the blood, changing its color from 
reddish purple to loam. This was followed by digestion using 0.5mg/ml of collagenase 
Type IV (Sigma) prepared in buffer 2 (67.0mM NaCl, 6.7mM KCl, 4.8mM CaCl2-H2O, 
101mM HEPES, BSA 1.5%, pH 7.4) for 5-7mins at a flow rate of 6-7ml/min. After that, 
the catheter was removed and the liver separated out in a crystallizing dish with buffer 1 
(142mM NaCl, 6.7mM KCl, 10mM HEPES, 1.5% BSA, pH 7.4). The Glisson’s capsule 
of the liver is peeled and liver cells shaked in the liquid. The cells were made to pass 
through 100µm filter followed by a 40µm filter to separate out single cells. Cells were 
centrifuges at 50xg for 3min to obtain pelleted hepatocytes. The pelleted hepatocytes 
were washed again in buffer 1 and buffer 3 (137mM NaCl, 4.7mM KCl, 0.7mM MgSO4, 
1.2mM CaCl2-2H2O, 10mM HEPES, 1.5% BSA, pH 7.4) to obtain ≥97% pure 
hepatocytes. The pellet is resuspended in growth media containing DMEM-High glucose, 
10% FBS, Penicillin/streptomycin, Glucagon (14ng/ml), Hydrocortisone (7.5µg/ml), EGF 
(20ng/ml) and Insulin (0.5U/ml) and cells plated in a 96-well collagen coated plates at a 
density of 0.015x106 cells per well. After 4-5 hours of attachment, the media was 
replaced with fresh growth media and cells used within 24hrs for experimentation. 
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6.3.Methods 
 
6.3.1.Evaluation of Kinetics of C1-BODIPY-C12 in different cell lines 
For each cell type, fatty acid transport kinetics were evaluated according to the method 
described in Arias-Barrau, et al. [57]. A range of C1-BODIPY-C12 concentrations, as 
specified in Figure 2.1, were used in a 5 min assay conducted in kinetic mode on a 
BioTek Synergy plate reader using Gen5.2 software. Uptake was measured every 5 sec.  
The substrate was presented to the cells as a complex with fatty acid-free BSA to give 
BODIPY-FA to BSA ratios of 0.5:1 to 20:1 (2.5-100 µM C1-BODIPY-C12 and 5µM 
BSA).  Non-cell associated fluorescence was quenched with trypan blue as described 
[55].  Uptake was measured at 485 nm excitation and 528 nm emission.  The level of C1-
BODIPY-C12 transported into the cell was calculated by conversion of the relative 
fluorescence units (RFU) to concentration of C1-BODIPY-C12 calculated from a standard 
curve generated for each lot of ligand. These experiments allowed the apparent KT and 
maximal rate (Vmax) of C1-BODIPY-C12 transport to be defined. The experiments were 
repeated three times in triplicate for each cell type and then the data was analyzed using 
Prism® 5.0 software. 	  
6.3.2.Evaluation of uptake inhibition by CB5  
HepG2 and INS-1E cells were maintained in a culture medium containing EMEM 
(MEM/EBSS plus 10% FBS) and RPMI-1640, respectively. Caco-2 cells were 
differentiated using epithelium differentiation media pack and maintained as detailed 
above. C2C12 cells were maintained and differentiated as detailed above. After 24hrs of 
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plating, cells were starved in MEM media (without phenol red) for 1hr at 37°C 5% CO2. 
After starvation, MEM media was replaced with 50µl of compounds (CB5 or atypical 
antipsychotics-in HepG2 cells) for treatment (ranging from 0.01µM-1000µM) prepared in 
MEM (MEM alone for controls) and incubated for another 1hr. After 1hr, 50µl of C1-
BODIPY-C12/BSA/Trypan blue (TB) (final conc. 5µM BODIPY-FA, 5µM FA-free BSA 
and 1.97mM trypan blue) solution was added to each well and incubated for 15 minutes 
at 37°C. The plate was read using a Biotek Synergy plate reader using Gen5.2 software at 
an excitation/emission of 485/528nm. The data was analyzed by non-linear regression fit 
using one-site competition and dose response models in Prism software (GraphPad 
Software Inc., San Diego, CA) to obtain IC50 values for each treated compound.  
Similar assay was used to determine the uptake inhibition of BODIPY FL C5 and 
BODIPY FL C16 in HepG2 and Caco-2 cells. 
 
6.3.3.Assessment of lipotoxicity and nuclear integrity in cells treated with palmitate 
HepG2 cells were plated on a 96-well plate at a density of 0.08X106 cells/well. After 
24hrs, the cells were treated with varying concentrations of PA (ranging from 500µM to 
0µM) in conjugation with BSA from a stock from 5mM PA/2mM BSA with or without 
CB5 (0-50µM).  For atypical antipsychotics, 50µM or 100µM [74, 111-113] of 
compounds were treated with 500µM or 100µM of PA for 24hrs. 24hrs post-incubation, 
30µM Nile-red (prepared in DMSO) was added, from a stock of 3mM, to each well in 
dark room and incubated for 30min at 37°C 5%CO2. The plate reader was set for shaking 
for 1min prior to read at excitation/emission of 485/590nm.  
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INS-1E cells were plated at a density of 0.2x106 cells per well and incubated for 96h. 
After 96hr, the cells were treated with varying concentrations of PA (ranging from 
500µM to 0µM) in conjugation with BSA from a stock from 5mM PA/2mM BSA with or 
without compound (0-50µM). After 24hrs, they were treated the same way as HepG2 to 
determine lipid accumulation using Nile red. 
 
Primary hepatocytes were isolated and plated on a collagen coated 96-well plate at a 
density of 0.015x106 cells per well in growth medium (as detailed above) and allowed to 
attach for 4-5 hrs. After 4-5hrs, the media was replaced with media containing 5mM 
PA/2mM BSA with or without CB5 and incubated at 37°C. After 24hrs of treatment with 
PA and CB5 (media only in case of controls), 30µM nile-red (prepared in DMSO) was 
added, from a stock of 3mM, to each well in dark room and incubated for 15 min at 37°C 
5%CO2. The plate reader was set for shaking for 1min prior to read at 
excitation/emission of 485/590nm. 
 
For assessing the nuclear integrity of the HepG2, INS-1E and primary hepatocytes cells, 
they were stained with 2µl of DAPI (4',6-diamidino-2-phenylindole (stock of 0.5mg/ml in 
water) per well and incubated for 30mins at 37C after 24hrs treatment with 500-0µM of 
PA/BSA with or without 5-50µM of CB5. After 30mins staining, the plate was read on 
the BioTek Synergy plate reader at an excitation/emission of 360/460 nm. 
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6.3.4.Screening, solubility, stability and dosage formulation studies 
Pharmacokinetic parameters of CB5 and CB16.2 in mice were determined in 
collaboration with Kansas University. For solubility and stability studies, CB5 and 
CB16.2 were dissolved in methanol and their extinction coefficient determined at a 
wavelength of 272 and 305nm respectively. For stability studies, different solutions were 
kept at different temperatures and time periods and the degradation of compound 
determined using UV spectroscopy. To determine the dosing formulation for different 
routes of administration and maximum drug tolerability by mice, 3 mice per time point 
(0-720 minutes) were administered with 2mg/kg CB5 or CB16.2 via IV and 4mg/kg of 
CB16.2 via IP or SQ prepared in solutol HS 15. At each time point, plasma sample was 
collected and subjected to LC/MS analysis to determine the concentration of compound 
in plasma.  
 
For measuring the levels of CB5 or CB16.2 in plasma samples, unknown plasma and/or 
control plasma was mixed with internal standard (IS) (analog of CB5 or CB16.2) 
prepared at a concentration of 550ng/ml in acetonitrile (ACN). This was followed by 
extraction using 0.1% trifluoroacetic acid (TFA) in water and a gentle vortex for 5mins in 
a multi-tube vortex. The samples were centrifuged at 13,000 rpm for 5 min and 
supernatant transferred to HPLC vials for analysis using LC/MS-MS.  For HPLC 
analysis, two mobile phases used were: Mobile Phase A-5/95/0.1 Acetonitrile/Deionized 
water/formic acid and Mobile phase B- 95/5/0.1 Acetonitrile/Deionized water/formic acid 
at a flow rate of 0.35ml/min and injection volume of 5µl. The HPLC gradient and mass 
spec settings are detailed below in Table 6.3A and 6.3B. The amount of CB5 or CB16.2 
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present in the blood was determined using a standard curve obtained using known 
concentrations of CB5 or CB16.2 (ranging 0.09 to 3.3ng/µl plasma) and the internal 
standard.  
 
6.3.5.Drug metabolism studies using liver microsomes in vitro 
For drug metabolism studies in mouse and human microsomes, a 200µM stock of CB5 
was prepared in DMSO and then diluted to get a final working concentration of 2µM 
CB5. Verapamil (200µM stock prepared in ethanol) was used as a positive control and a 
negative control was a sample run without NADPH in the presence of verapamil at 60 
minutes. Samples were prepared with 20 mg/ml microsomes (final concentration 
0.5mg/ml), PBS (pH 7.4), ultra pure water and 200µM verapamil or CB5 (final 
concentration 2µM). Four different time points were used for the test compound-0, 15, 30 
and 60 minutes and two time points for the positive control-0 and 60minutes. To initiate 
the reaction, 50µl of 10mM NADPH was added to each tube and gently vortexed. For the 
negative control, ultra pure water was added instead. This was followed by incubation at 
37°C shaking water bath. For zero minute time point samples, 250µl of ice-cold 
acetonitrile (ACN) was added to the tubes immediately to stop the reaction and tubes set 
aside for next step. At appropriate time points, ice-cold ACN was added to other tubes 
too. The tubes were then centrifuged at 10,000xg for 5 minutes at 4°C and the 
supernatant were transferred to HPLC vials for analysis by LC/MS/MS. The method used 
for detection of CB5 in the samples is same as described above.  
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6.3.6.Determining the pharmacokinetics of CB5 and CB16.2 in C57Bl/6 mice 
Eleven weeks old C57BL/6 (catalog no. 000664) male mice were obtained from Jackson 
laboratories and kept in quarantine for 1 week on normal chow diet. Animals were 
housed in the AAALAC approved facility at the University of Nebraska – Lincoln (UNL) 
in ventilated cages at 22˚C with a 14/10 h day/night cycle and were allowed free access to 
water and standard laboratory chow (2016 Teklad Global 16% Protein Rodent Diet 
(Harlan Laboratories)).  All animal studies were reviewed and approved by the 
Institutional Animal Care and Use Committee of UNL. 
 
To assess inhibition of fatty acid uptake, mice were treated with either vehicle (flaxseed 
oil) or 300mg/kg of CB16.2 or CB5 prepared by dissolving in DMSO and then volume 
made up with flaxseed oil. Vehicle consisted of same volume of DMSO as in compounds. 
There were 36 mice per group with 8 mice at each time point-0.5, 2 and 6hr for control 
and CB16.2 and 12 mice at each time point for CB5. After 12hrs of fasting, mice were 
injected with 500mg/kg of tyloxapol in PBS (intraperitoneal injection) and gavaged with 
CB5, CB16.2 or vehicle. One hour after compound (CB16.2 or CB5) administration, 
mice were given a bolus of flaxseed oil containing 500mg/kg of 13C18 oleate. Blood was 
collected via cardiac puncture in EDTA-treated tubes at 0.5, 2 and 6 hrs following the 
gavage of labeled oleate. Plasma was separated out from the whole blood and subjected 
to further analysis. 
 
For measuring the uptake of oleate, plasma (25µl) was extracted by modification of Folch 
et al [84]. Briefly, lipids were extracted from plasma samples using chloroform/methanol 
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2:1 vol:vol containing 0.05% BHT (butylated hydroxytoluene). Methyl ester formation 
was carried out using 1% sulfuric acid in methanol and toluene at 50°C overnight. Next 
day, the lipids were washed and separated out in hexane phase, dried under N2 and 
resuspended in 50µl of methyl acetate for analysis using GC/MS. Samples were analyzed 
using an Agilent 7890A gas chromatography unit linked to an Agilent 5975C VL MSD 
(mass selective detector) (Agilent, Palo Alto, CA) using electron impact ionization. GC 
was performed using an Agilent CP7421 Select FAME column, 200 m X 275 µm X 0.25 
µm. Samples (1µl) were injected in a splitless mode with selective ion monitoring (SIM). 
The mass selective detector was set for selective ion monitoring of m/z 296 for the methyl 
ester of endogenous 12C oleate and m/z 314 for the methyl ester of 13C18 oleate, using 
100ms dwell time per ion.  
 
Table 6.3A: HPLC settings used for the detection of compounds in plasma samples. 
Time 
(min) Module Events Parameter 
1.00 Pumps Pump B Conc. 20 
3.00 System Controller Event 0 
4.00 Pumps Pump B Conc. 95 
5.50 System Controller Event 1 
6.00 Pumps Pump B Conc. 95 
6.10 Pumps Pump B Conc. 20 
10.00 System Controller Stop 
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Table 6.3B: Mass Spectrometer settings for the detection of ions specific to compounds as 
used for detection using LC/MS/MS. Internal standards, CB16.104 and CB5.5, used along with 
CB16.2 and CB5 respectively. 
 
Q1 Q3 
Tim
e(m
sec) 
DP 
E
P 
C
E 
CX
P 
CUR 
GAS 
CA
D 
IS 
CUR 
TE
M 
GS
1 
GS
2 
ID
H 
CB16.2 359.96 121.1 200 47 6 34 6 15 Med 5500 400 70 70 On 
CB16.104 287.19 120.867 200 35 6 26 6 15 Med 5500 400 70 70 On 
CB5 457.1 411.1 200 120 6 44 6 15 Med 5500 400 70 70 On 
CB5.5 453.4 407.2 200 120 6 42 6 15 Med 5500 400 70 70 On 
 
 
6.3.7.Effect of high fat and low fat diet on FATP2 KO and WT mice 
All animals were housed in the AAALAC approved facility at the University of Nebraska 
– Lincoln (UNL) in ventilated cages at 22˚C with a 14/10 h day/night cycle and were 
allowed free access to water and standard laboratory chow (2016 Teklad Global 16% 
Protein Rodent Diet (Harlan Laboratories)). All animal studies were reviewed and 
approved by the Institutional Animal Care and Use Committee of UNL. 
 
FATP2 KO (Strain: 129S6/SvEv) mice were recovered from cryopreservation from 
Jackson Labs (cat.# 005066) and bred in our animal facility. They were weaned at 4 
weeks of age and kept of normal rodent chow diet before the start of experiment. Wild 
type 129S1/SvImJ (catalog no.002448), used as controls, were obtained from Jackson 
laboratories and at 4weeks of age and kept in quarantine for 1 week on normal chow diet. 
All the animals were put on high fat (HF) (60% energy from fat) and low fat (LF) (12% 
energy from fat) (TestDiet-58G9 and 58G7, respectively) diets starting at the age of 5 
weeks and continued for 12 weeks. The cages and food was changed every 2 days for all 
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the animals. Body weights and tail bleeds were collected every week after 4hrs of fasting. 
Commercially available kits were used for determining levels of triglycerides, (Wako 
Chemicals, Richmond, VA), ketone body (Sigma, MAK134), insulin (ultrasensitive 
mouse insulin ELISA, cat.# 90080, Crystal Chem Inc.) and leptin (Mouse leptin-cat.# 
EZML-82K, 96-well plate assay ELISA kits from EMD Millipore, MA) in plasma. 
Glucose levels were determined every other week using handheld ACCU-Chek Aviva 
Plus blood glucose monitoring system (Roche Diagnostics). After 12 weeks, mice were 
sacrificed after 4 hr of fasting, blood collected via cardiac puncture and different tissues 
were harvested and stored at -80°C for analysis. 
 
6.3.8.Lipid analysis of liver tissue and fecal samples 
For lipid analysis of liver tissue, modified Folch method [84] was used. Briefly, 50mg of 
liver tissue was homogenized using a homogenizer in chloroform: methanol, 2:1 vol:vol 
containing 0.05% BHT (butylated hydroxytoluene) and 100ug of C19:0 internal standard 
and kept for vortexing for 1hr. The organic phase was separated from the tissue debris by 
centrifugation for 10mins at 2500rpm. One-fourth volume of water was added to the 
organic phase, vortexed followed by centrifugation. Two phases will be visible. The 
lower phase is separated carefully to a new glass tube and dried under the stream of 
nitrogen. To these dried samples, 1ml of chloroform was added, vortexed and divided 
into two sets of 500ul each. One set of 500ul was used for liver triglyceride analysis 
using Wako kit, whereas other half continued for the formation of methyl esters using 1% 
sulfuric acid in methanol and toluene at 50°C over-night. Next day, the fatty acid methyl 
esters were extracted in hexanes and washed using 1% potassium chloride. The hexane 
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samples were dried through a column containing anhydrous sodium sulfate and flow 
through collected. The flow through was then dried under the stream of nitrogen and 
resuspended in 250ul of methyl acetate before analysis using GC/MS. The samples were 
run on GC/MS with a column specific for FAMES (fatty acid methyl esters) using 1ul 
injection volume and the obtained chromatogram analyzed using NIST11.L library. 
 
Same method was used for the extraction of lipids from the feces. Fecal pellet were dried 
in a vacuum heater for 1hr on medium heat to get rid of any water. The pellets were 
weighed after drying and then subjected to lipid extraction as detailed above. 
 
For liver triglyceride analysis, the samples (obtained from extraction as detailed above) 
were dried under a stream of nitrogen and then resuspended in 200ul of isopropanol. The 
assay for determining the levels of triglycerides in liver tissue was carried out as per the 
Wako kit instructions. 
 
6.3.9.Evaluation of expression of FATP genes in primary hepatocytes using qPCR 
Primary hepatocytes were isolated from 129S1/SvImJ WT and 129S6/SvEv FATP2 KO 
mice as detailed above. After isolation, approximately 1x107 cells were pelleted by 
centrifugation and RNA extracted using RNAeasy Mini Kit (catalog no. 74106, Qiagen) 
as per kit instructions. One microgram of RNA was used to synthesize cDNA using 
iScriptTM cDNA synthesis kit (catalog no. 170-8891, Bio-Rad) as per kit instructions. 
Quantitative PCR synthesis was carried out in a 96-well plate format using Bio-Rad 
iCycler. Each Q-PCR reaction contained the following: 12.5µL of BioRad iQ SYBR 
	  	  
121	  
Green Supermix, 500nM of each primer (Table 6.3C), 1 µL cDNA, and filter purified 
H2O up to a total volume of 25µL. A standard curve was generated for all genes studied 
using serial dilutions of the corresponding PCR product using the primers specified.  The 
PCR products had been previously purified using a Qiagen PCR purification kit and the 
concentration measured using a NanoDrop®.  Each gene was expressed as number of 
copies relative to those measured for β-actin within the same RNA sample. Similarly, 
20µg of liver samples from WT and KO fed HFD and LFD animals were used for RNA 
extraction and qPCR analysis as detailed above.  
 
 
6.3.10 Statistical analysis 
A minimum of 3 experiments, each assayed in triplicate, were used for statistical 
comparison as stated within the legends of the figures. Data were compared using JMP 
v11 analysis software (SAS Inst., Inc., Cary, N.C., USA). Significance of difference was 
determined using ANOVA, Student's paired t distribution, or bivariate fit Y by X. Values 
were considered statistically significant at p <0.05.
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Table 6.3C: Forward and Reverse Primers used for QPCR analysis in hepatocytes and liver 
samples obtained from mice fed normal chow; and high fat and low fat diets, respectively. 
Gene Primers NCBI reference sequence 
β-actin 
(control) 
Fwd: 5'-TGT GAT GGT GGG AAT GGG TCA GAA-3' 
NM_007393.3 
Rev: 5'-TGT GGT GCC AGA TCT TCT CCA TGT-3' 
FATP1 gene 
Fwd: 5'-TGG TCA AGG TCA ATG AGG ACA CGA-3' 
NM_011977.3 
Rev: 5'-ACG CTG TGG GCA ATC TTC TTG TTG-3' 
FATP2 gene 
Fwd: 5’-CTG GAC AAA GTA GAC GGA GTG-3’ 
NM_011978.2 
Rev: 5’-CTG TGG TTC CCG AAG TAT AAA-3’ 
FATP4 gene 
Fwd: 5’-AGT AAG CAT GTG GCT TTG GGC AAG-3' 
NM_011989.4 
Rev: 5'-TTT GGC AGA AGA TGG AGC AAC AGC-3' 
FATP5 gene 
Fwd: 5'-TGT AAC GTC CCT GAG CAA CCA GAA-3' 
NM_009512.2 
Rev: 5'-ATT CCC AGA TCC GAA TGG GAC CAA-3' 
FATP6 gene 
Fwd: 5'-TTG GGA CCG TCT TGG AGA CAC TTT-3' 
NM_001081072.1 
Rev: 5'-TGC TTC CTG GAT GAA GTC CAA CCT-3' 
ACSL1 gene 
Fwd: 5’-TGC AGC GAG TGT GGG AAA G-3’ 
NM_007981.3 
Rev: 5’-TGG TAA GAC CCC GTG GAC-3’ 
ACSL3 gene 
Fwd: 5’-TTC CTT CCC CTG CTC CAG T-3’ 
NM_001033606.2 
Rev: 5’-CGA TTC TGA AAA AGT CTC CTG TTG-3’ 
ACSL4 gene 
Fwd: 5’-GGG CAA ATA AAA TGC GGC T-3’ 
NM_001033600.1 Rev: 5’-GGC TTA AAC TCT AGA ACT AAA AAC CAT 
CA-3’ 
ACSL5 gene 
Fwd: 5’-TCG ATG CAA TGC CTG CAC T-3' 
NM_027976.2 
Rev: 5’-TGC AGG GAC TGA AGG CCA-3' 
**Fwd: forward primer; Rev: reverse primer. 
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